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ABSTRACT 
The dissolution and permeation of active ingredient from its carrier system are the key 
factors in affecting its efficacy. An ability to control active ingredient’s rate of release 
not only enable optimum therapeutic effect but also lower the possibility of adverse 
effect. This study aimed to investigate the physicochemical properties, encapsulation 
efficiency and release profile of four types of nanocarrier with different disperse and 
continuous phases. The four nanocarriers include (i) nanostructured lipid whereby the 
lipid matrix is dispersed in aqueous phase; (ii) liposome consists of outer lipid bilayer 
and aqueous core which also dispersed in aqueous phase; (iii) water-in-oil 
microemulsion has water droplet as disperse phase and olive oil as continuous phase; 
last but not least, (iv) κ-carrageenan-chitosan nanoparticle which has hydrophilic 
polymer dispersed in aqueous phase. Three low molecular weight active ingredients 
with different solubility in water which are ascorbic acid, caffeine and lidocaine were 
then encapsulated in those nanocarriers. Based on the physicochemical evaluations, the 
formulated nanocarriers were stable for at least 30 days with polydispersity of < 0.4 
when kept at 30 ˚C. The particle sizes of nanocarriers were in the ascending order of 30 
nm, 100 nm, 250 nm, and 400 nm for microemulsion, liposome, nanostructured lipid, 
and κ-carrageenan-chitosan nanoparticle respectively. Encapsulation efficiency revealed 
that liposome and nanostructrured lipid which have lipid surface, were excellent for 
lidocaine encapsulation up to 80% while water-in-oil microemulsion and κ-carrageenan-
chitosan nanoparticle have better preference towards more water soluble ascorbic acid 
with 70% encapsulation efficiency. All nanocarriers exhibit controlled release property 
whereby the active ingredients’ rates of release from those nanocarriers were slower 
than free active ingredients. The average time required for in vitro 50% active 
ingredients to be released from nanocarriers were in the order of liposome (7 hours), 
nanostructured lipid (9 hours), water-in-oil microemulsion (33 hours), and lastly, κ-
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carrageenan-chitosan nanoparticle (more than 48 hours) irrespective to the types of 
active ingredients. The reason for a shorter time to achieve 50% release in liposome and 
nanostructured lipid is due to initial burst release from the surface of the nanocarrier 
which is then followed by sustained release from the matrix core. Nanostructured lipid 
which requires longer release time than liposome was accountable to the fact that longer 
diffusion path length for the homogenized nanocarrier to diffuse due to its larger size. 
The extended period of release time for water-in-oil microemulsion is plausibly due to 
interfacial barrier and different permeability coefficient of donor and receptor chamber 
in Franz diffusion cell. κ-carrageenan-chitosan nanoparticle which extensively 
prolonged the release time could be attributed by electrostatic interaction between the 
active ingredients and the polymer. The in vitro release profile of those nanocarriers 
showing that they could be tailored for different applications, hence aided in solving 
solubility and permeability problems, enhancing therapeutic effects and lastly, 
minimizing or eliminating possible side effects. 
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ABSTRAK 
Kelarutan dan penelapan ramuan aktif adalah faktor-faktor utama yang mempengaruhi 
efikasi ramuan aktif dalam sistem penghantaran. Kebolehan untuk mengawal kadar 
pembebasan ramuan aktif bukan hanya memberi kesan terapeutik yang optimum tetapi 
juga membantu mengurangkan kesan sampingan. Objektif penyelidikan ini adalah 
untuk mengkaji sifat fisikokimia, kecekapan pengkapsulan dan profil pembebasan 
ramuan aktif daripada empat jenis sistem penghantaran yang mempunyai fasa sebaran 
dan fasa berterusan yang berbeza. Empat sistem penghantaran yang dikaji adalah (i) 
lipid struktur nano dimana matriks lipid tersebar dalam akues; (ii) liposom mempunyai 
lipid dwilapisan luar dan akues teras yang juga tersebar dalam akues; (iii) emulsimikro 
air dalam minyak terdiri daripada butiran air sebagai fasa sebar dan minyak zaitun 
sebagai fasa berterusan serta (iv) zarah nano κ-karagenan-kitosan dimana polimer 
hidrofilik tersebar dalam akues. Tiga ramuan aktif yang mempunyai berat molekul yang 
kecil serta keterlarutan air yang berbeza iaitu asid askorbik, kafein dan lidokain telah 
dikapsulkan dalam sistem penghantaran tersebut. Berdasarkan penilaian fisikokimia, 
apabila sistem penghantaran tersebut disimpan pada suhu 30 ˚C, ia adalah stabil dengan 
kepoliserakan yang kurang daripada 0.4 selama sekurang-kurangnya 30 hari. Purata saiz 
zarah sistem penghantaran emulsimikro, liposom, lipid struktur nano dan zarah nano κ-
karagenan-kitosan adalah masing-masing 30 nm, 100 nm, 250 nm dan 400 nm. 
Kecekapan pengkapsulan menunjukkan bahawa liposom dan lipid struktur nano adalah 
sesuai untuk mengkapsul lidokain iaitu sebanyak 80% manakala emulsimikro air dalam 
minyak dan zarah nano κ-karagenan-kitosan yang lebih sesuai untuk asid askorbik yang 
lebih larut dalam air, mempunyai kecekapan pengkapsulan sebanyak 70%. Semua 
sistem penghantaran menunjukkan sifat pembebasan terkawal dimana kadar 
pembebasan ramuan aktif dari sistem penghantaran adalah lebih perlahan berbanding 
ramuan aktif yang tidak dikapsulkan. Purata masa yang diperlukan untuk membebaskan 
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50% ramuan aktif dari sistem penghantaran secara in vitro tanpa mengambil kira  jenis 
ramuan aktif adalah meningkat daripada liposom (7 jam), lipid struktur nano (9 jam), 
emulsimikro air dalam minyak (33 jam) dan zarah nano κ-karagenan-kitosan (lebih 
daripada 48 jam). Liposom dan lipid struktur nano memerlukan masa yang lebih pendek 
berikutan peletusan awal dari permukaan sistem penghantaran seterusnya pembebasan 
tertahan dari matriks teras. Lipid struktur nano memerlukan masa yang lebih lama 
berbanding liposom dalam pembebasan ramuan aktif disebabkan oleh saiz partikel yang 
lebih besar maka laluan peresapan yang lebih panjang bagi sistem penghantaran tersebut. 
Masa pembebasan yang diperpanjangkan oleh emulsimikro air dalam minyak adalah 
berkemungkinan kerana sawar antara muka dan koefisien ketelapan yang berbeza pada 
bahagian penderma dan penerima ‘Franz diffusion cell’. Zarah nano κ-karagenan-
kitosan yang mempunyai masa pembebasan yang diperpanjangkan secara ekstensif 
adalah disebabkan oleh interaksi elektrostatik antara ramuan aktif dan polimer. 
Berlandaskan profil pembebasan in vitro, sistem penghantaran yang dikaji boleh 
dikhususkan untuk aplikasi yang berbeza supaya dapat menyelesaikan masalah 
kelarutan dan penelapan, mempertingkatkan kesan terapeutik dan juga mengurangkan 
atau menghapuskan kesan sampingan ramuan aktif. 
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CHAPTER 1: INTRODUCTION 
The term nanotechnology was first used in 1974 by Norio Taniguchi (Dusastre, 2008) 
whilst the massive advancement of nanotechnology was advocated by Bill Clinton in 
National Nanotechnology Initiative program in year 2000. Malaysia introduced 
Economic Transformation Program (ETP) in 2009 while nanotechnology was given a 
high level of attention in this plan. Through this initiative, there is a breakthrough in the 
field of medical therapy. The attention is mainly focused on solving the solubility and 
permeability problems of active ingredients using specially designed vehicles for 
specific and safer treatment. In earlier days, treatment is limited to direct application of 
active ingredient which blended in matrix or as colloidal dispersion in the form of tablet, 
emulsion, gel and/or aerosol. Nevertheless, these treatments sometimes could not reach 
its optimum efficacy as well as generate adverse effects after chronic exposure to the 
potent active ingredients. Thus, more sophisticated nano-sized carriers such as liposome, 
dendrimer, nanocrystal, hydrogel were fabricated to address the issues and modulate 
active ingredients’ delivery. 
 
1.1 Solvent solubility and bioavailability of active ingredients 
Despite that the human’s body is made up of 70% water, the skin is covered by 
hydrophobic layer of cells. For this reason, it is crucial that the active ingredient will be 
able to solubilize in aqueous phase when its presence in the body or permeate through 
hydrophobic layer of the skin, which then followed by absorption into systemic 
circulation until it reaches site of action. This mechanism is known as the active 
ingredients solubility and bioavailability. The term solubility, is defined as the amount 
of solvent required to dissolve 1 g of solute while bioavailability, is the amount and rate 
at which a substance is absorbed and available at the site of physiological activity in 
living system. Based on the solubility and permeability, active ingredients were 
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categorized into four groups in biopharmaceutical classification as in Table 1.1 while 
the amount of solvent required to dissolve 1 g of solute is shown in Table 1.2 (Dahan et 
al., 2009; Kawabata et al., 2011). 
 
Table 1.1: Biopharmaceutical classification system of active ingredients 
Class Solubility Permeability Absorption 
I High High Good 
II Low High Variable 
III High Low Variable 
IV Low Low Poor 
 
  
Table 1.2: Amount of solvent needed to dissolve 1 g of solute 
Solubility Amount of solvent required (ml) 
Very soluble Less than 1 
Freely soluble 1 to 10 
Soluble 10 to 30 
Sparingly soluble 30 to 100 
Slightly soluble 100 to 1000 
Very slightly soluble 1000 to 10000 
Practically insoluble Greater than 10000 
 
 
For Class I active ingredient that has the properties of high solubility and permeability, 
it gives rise to a greater absorption rate than excretion rate. Thus, Class I active 
ingredient has a higher bioavailability over time. For Class II active ingredient with the 
properties of low solubility but high permeability, problems arise many times because 
of inadequate dissolution rate. As a consequence, further understanding in the 
enhancement of active ingredients’ solubility is required. For Class III active ingredient 
with the properties of high solubility but low permeability, its bioavailability gets 
limited at the site of action. Hence, attention is being focused on the materials as well as 
methods for the preparation of formulation. Finally, Class IV active ingredient with the 
properties of low solubility and permeability, requires both approaches taken for both 
Class II and III active ingredient to enhance dissolution rate and improve its 
bioavailability. The classification is essential for oral delivery. However, for topical 
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delivery, the ability of active ingredient to penetrate through hydrophobic skin cell layer 
is important for its absorption. As a consequence, active ingredient classified in both 
Class III and IV in reverse could have a better permeability than those of Class I and II. 
 
The rate of release of active ingredient depends on the features of the nanocarrier to 
encapsulate and control active ingredient’s release. For instance, fast dissolution rate of 
Class I active ingredient could be regulated by trapping it in three dimensional hydrogel 
while enhancement of solubility and permeability of Class IV active ingredient can be 
achieved by using lipid nanoparticle. These innovations could contribute to more 
targeted delivery depending on its pathway and so reduce the possibilities of adverse 
effects that arise from active ingredients’ accumulation.  
 
1.2 Active ingredients’ delivery pathways  
The therapeutic effect of active ingredients can be either localized or systemic 
depending on its delivery pathways. Most of the time, localized effect implicates topical 
delivery while systemic effect can be carry out via oral, parenteral, nasal or ophthalmic 
pathway (Figure 1.1). 
 
 
Figure 1.1: General pathways for active ingredients’ delivery 
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Among the various types of delivery pathways, topical delivery gains a lot of attention 
as it could avoid first-pass metabolism and enzymatic breakdown. Hence, it will 
indirectly minimize the possible degradation of active ingredients that experienced in 
oral delivery as well as pain that caused by injection in intravenous delivery. Therefore, 
the major challenge in topical delivery is the route of active ingredients to penetrate 
through the skin down into the circulatory system. If active ingredients could easily 
permeate through the skin, this delivery might be one of the best ways for treatment.  
 
The skin is the largest organ of the body. It consists of three main layers which include 
epidermis, dermis and subcutaneous tissue with different structures and functions. In 
topical delivery, the main barrier to overcome during active ingredient’s permeation is 
the topmost epidermis layer. Epidermis is a multi-layered membrane with a thickness of 
60-80 µm. This complex membrane is made up of four distinct layers, which are 
stratum corneum, stratum granulosum, stratum spinosum and stratum basale counted 
from the outer layer. Stratum corneum, the protective layer of the skin is roughly 10 µm 
thick. Nevertheless, due to its unique constituents, the hydrophobic layer sets as a 
barrier in preventing the penetration of substance with a particle size larger than 40 nm 
(William, 2003).  
 
In topical delivery, active ingredients can permeate through the epidermis via shunt, 
intracellular and intercellular route. Shunt route allows diffusion of active ingredients 
bypassing stratum corneum, thus directly into dermis layer via pores of hair follicle and 
sweat ducts. Intracellular pathway requires multiple partitioning and diffusion steps 
throughout the epidermis. Intercellular route enables components to directly diffuse and 
reach dermis layer without those steps in intracellular pathway (Prow et al., 2011). On 
that account, a suitable delivery carrier could be prepared to suit those permeation 
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routes, for examples, by formulating delivery carrier with a size below 40 nm or particle 
with lipophilic properties.  
 
1.3 Drug delivery carrier 
Numerous delivery carriers such as micelle, vesicle, lipid dispersion and nanoparticle 
dispersion with a particle size less than 500 nm were developed to enhance active 
ingredient’s encapsulation, control the rate of release and provide better penetration to 
the targeted site. This could reduce active ingredient’s wastage, prevent possible 
adverse effect and decrease the degradation of active ingredients through high 
encapsulation and controlled release. 
 
Effective encapsulation and sustained release of active ingredients could reduce the 
dosage that required for effective therapeutics. Polymeric micelle which consists of 
hydrophobic core-shell and hydrophilic surface, is suitable for the encapsulation of 
hydrophobic active ingredients (Zhang et al., 2012) while hydrogel with polymeric 
networks could be more effective in the entrapment of hydrophilic active ingredients 
(Chen et al., 2011). Apart from that, sustained release of active ingredients can reduce 
cell cytotoxicity by improving their distribution and prevent their accumulation in the 
body. Zhang et al. (2012) proved that nanostructured lipid-dextran sulfate hybrid 
carriers with high encapsulation efficiency can sustain the release of mitoxantrone 
hydrochloride for 72 hours and thus enhance the therapeutic effect as compared to the 
free active ingredient.  
 
Active ingredients can be easily metabolized, degraded or cleared by the body system 
through enzymatic digestion, oxidation and mononuclear phagocytic system (MPS) 
uptake respectively (Li and Huang, 2008). For that reason, delivery carrier which coated 
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with polyethylene glycol (PEG) or hyperbranched polyglycerol (HPG) can prolong its 
circulation time by increasing surface hydrophilicity, hindrance of negative surface 
charge and improving resistance to adsorption (Allen and Martin, 2004; Deng et al., 
2014). Besides that, nanocarrier with a multi-layered structure such as aquasomes, could 
prolong the release time of recombinant human interferon-α-2b for combating ovarian 
cancer cells (Kaur et al., 2015). Other than that, matrix core of delivery carrier acts as a 
barrier to prevent active ingredient from environment degradation, thereby extends its 
shelf-life. Solid lipid nanocarrier (SLN) with a flexibility in modulating the rate of 
active ingredient’s release, hence protecting the active ingredient from chemicals, 
photochemical and oxidative degradation (Chinsriwongkul et al., 2011).  
 
1.4 Characterization of delivery carrier 
Delivery carrier usually presents in the form of colloidal system, whereby the particle is 
evenly distributed in the continuous phase. Physicochemical characteristics of a 
prepared formulation will highly affect its stability and efficacy. On that account, an 
easy yet significant way to evaluate the stability of a formulation is through visual 
observation. Destabilization of colloidal system will induce separation of the 
formulation into respective immiscible phases via coalescence, flocculation and/or 
Ostwald ripening (Badolato et al., 2008; Somasundaran et al., 2007). Besides that, 
changes in the turbidity of the suspension also may be taken as an indication of 
instability. When lipid nanoparticle was monitored using spectrophotometer at the 
wavelength of 200-800 nm hourly for 72 hours, it was shown that the transmittance 
increased after 24 hours. This is a phenomenon whereby the lipid nanoparticle becomes 
unstable and it flocculates to form an oil layer on top of the formulation. 
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Apart from visual observation, a more accurate way to evaluate the stability of a 
formulation is through the determination of particle size and zeta potential by 
employing zetasizer. Small particle size and zeta potential with a magnitude which is 
higher or lower than ±30 mV are usually categorized as highly stable. This stability is 
attributed by net forces of attraction and repulsion between the particle, vesicle or 
droplet. These net forces are contributed by electrostatic force, van der Waals force, 
hydrophobic and hydrophilic forces. When the particle, vesicle or droplet comes closer 
to each other, electrical double layer surrounding its surface may acts as a barrier to 
prevent destabilization of the formulation. Other than that, thermal stability is an 
important feature especially for topical formulation. The delivery carrier can be 
designed as a thermal sensitive carrier, whereby those encapsulated active ingredients 
will be released at the designated temperature. On account of that, during logistic and 
storage, we have to ensure that the storage temperature is kept below 30 ˚C to prevent 
the destabilization of formulation. In addition, by examining the morphology of sample 
under optical polarizing microscope (OPM) or transmission electron microscope (TEM), 
it could be confirmed that the sample is well dispersed without any possible aggregation. 
 
Apart from physicochemical characteristics, a major concern in the design of delivery 
carrier is its abilities to encapsulate and release active ingredients. The encapsulation 
efficiencies of active ingredients depend on their compatibility with delivery carrier. 
Oil-in-water emulsion and lipid nanoparticle which entrapped active ingredients in the 
oil droplet and lipid core respectively, is a better approach for the encapsulation of 
hydrophobic active ingredients. On the other hand, an active ingredient which is more 
hydrophilic has a higher tendency to be entrapped in hydrogels and water-in-oil 
emulsion. Other than that, bilayer vesicle and double emulsion could incorporate both 
the hydrophobic and hydrophilic active ingredients. Through the understanding of those 
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chemical constituents, we also can encapsulate water soluble active ingredients in lipid 
core and vice versa. Apart from encapsulation, the ability of delivery carrier to control 
rate of active ingredients’ release, makes it promising for different applications. The 
release can be either in the form of fast release, controlled release or prolonged release. 
A good understanding of the release profile could provide insight on the most preferable 
route for delivery, thereby optimized the therapeutic effects.  
 
1.5 Aims of research 
The aims of our studies are: 
 To formulate or fabricate different types of drug carrier systems for delivery; 
 To determine and select the best formulation in each system based on their 
physicochemical properties;  
 To encapsulate active ingredients with varied solubility in water into carrier system 
and determine their release profile;  
 To compare, select and comment on the system prepared based on the results 
obtained. 
 
1.6 Outline of research 
There are five main chapters in this thesis. The first chapter includes the introduction of 
this research and aims to be achieved. Chapter 2 describes about the delivery system 
and their advantages for application. Chapter 3 presents the methods and approaches 
used in the design of experiments. Chapter 4 displays the results obtained via different 
characterization and discusses the significance of those results. Chapter 5 summarizes 
the findings and proposes potential future work that can be done. 
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CHAPTER 2: LITERATURE REVIEW 
Colloid is any particle with typical dimensions ranging from 10 to 1000 nm that 
dispersed throughout another substance. The particles are too small to be viewed with 
an ordinary light microscope, nonetheless, they are incapable of passing through the 
semi-permeable membrane. One of the commonly found colloid is emulsion in the form 
of either oil-in-water or water-in-oil dispersion of two immiscible liquids. Oil-in-water 
dispersion has refreshing and oil-free texture while water-in-oil dispersion could 
enhance penetration and reduce transepidermal water loss (TEWL). Thus, delivery 
carriers with different dispersed and continuous phase were explored for their 
physicochemical properties, active ingredients’ encapsulation efficiency and active 
ingredients’ release profile. In this research, four types of delivery carriers, namely 
nanostructured lipid, liposome, water-in-oil microemulsion and κ-carrageenan-chitosan 
nanoparticle were prepared. Nanostructured lipid is lipid matrixes disperse in aqueous 
solution; liposome is lipid bilayers with aqueous core disperse in aqueous solution; 
water-in-oil microemulsion has aqueous droplets disperse in oil continuous phase while 
κ-carrageenan-chitosan nanoparticle has hydrophilic polymer stabilized in aqueous 
surrounding. The carriers were encapsulated with active ingredients of varied solubility 
in water to evaluate the most suitable carrier for higher encapsulation efficiency. 
Release profile provides the rate of release for prediction of possible delivery pathways.  
 
    
NLC Liposome 
Water-in-oil 
microemulsion 
κ-carrageenan- 
chitosan nanoparticle 
Oil-in-water Water-oil-water Water-in-oil 
Hydrophilic polymer in 
water 
Figure 2.1: Delivery vehicles for active ingredients’ solubilisation and permeation 
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2.1 Nanostructured lipid  
The concept of lipid nanocarrier arises from oil-in-water emulsion, whereby the oil is 
fully or partially replaced by crystallized lipid that stabilized by surfactants (Müller et 
al., 2002a). Lipid nanoparticle is either in the form of solid lipid nanoparticle or 
nanostructured lipid carrier (NLC), bearing particle size less than 1000 nm. SLN being 
the first generation lipid nanoparticle, was prepared by single or blend type of solid 
lipids (Müller et al., 2007). SLN with high ordered crystalline is capable to encapsulate 
both hydrophobic and hydrophilic active ingredients for prolonged release. The slow 
release kinetic is plausibly due to lower diffusion rate of active ingredients from the 
crystallized matrix core (Müller et al., 2002b; Weiss et al., 2008). Nevertheless, the 
crystallinity limits the loading capacity and stability of SLN. This is plausibly due to the 
perfect arrangement in SLN which leads to drug expulsion. In order to overcome the 
problems, second generation lipid nanoparticles known as NLC was introduced 
(Pardeike et al., 2009). 
 
NLC is derived from SLN by replacing certain percentage of solid lipid with liquid lipid. 
This substitution creates an imperfect lipid matrix with higher fluidity, aid in enhancing 
active ingredients’ loading capacity (Yuan et al., 2007). This was observed in 
clotrimazole encapsulated SLN and NLC, whereby NLC showed higher entrapment 
efficiency compared to SLN (Souto et al., 2004a). In conjunction with the imperfection, 
liquid lipid reduces the melting temperature of lipid nanoparticle. Even so, there is 
always a limitation in the amount of liquid lipid that could be introduced into the NLC 
due to temperature factor. As a consequence, it is important to ensure that NLC still 
remains as solid particle at least at body temperature of 37 ˚C; otherwise it could be just 
an oil-in-water dispersion (Severino et al., 2011; Souto and Müller, 2008). Besides that, 
NLC works well in encapsulating Class II active ingredients. Lutein which falls in this 
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class has better solubility and permeability across synthetic membranes while prepared 
lipid nanoparticle with small particle size further enhance the permeation process (Mitri 
et al., 2011).  
 
2.1.1 Lipids and emulsifier for NLC 
Cetyl palmitate, glyceryl monostearate and stearic acid are commonly used as solid lipid 
in preparation of NLC. Cetyl palmitate, an ester derived from palmitic acid and cetyl 
alcohol, has good moisturizing effect. Thus, it serves as emollient to keep the skin moist 
and comfortable (Carbone et al., 2014; Kovacevic et al., 2011; Teeranachaideekul et al., 
2008). Glyceryl monostearate which is a glycerol ester of stearic acid, gives lubricant 
effect thereby reduces friction and eases spreading of formulation (Bhalekar et al., 2009; 
Kotikalapudi et al., 2012; Nayak et al., 2010; Ranpise et al., 2014). Stearic acid, a fatty 
acid with smoothing effect on the skin and neutral effect on both the cholesterol and 
blood lipids, is suitable as solid lipid in NLC (Pandita et al., 2014; Rahman et al., 2014; 
Woo et al., 2014).  
 
Medium chain triglyceride and oleic acid are liquid lipids found in NLC formulation. 
Medium chain triglycerides such as caprylic- and capric-triglyceride have many 
nutritional benefits, especially for the purposes of fat mass reduction and therapeutic 
effect for brain disorder (Doktorovová et al., 2010; Freemantle et al., 2006; Hu et al., 
2008; Severino et al., 2011; Zhang et al., 2015). Oleic acid, which helps in modulating 
immune responses thereby enhancing cutaneous wound healing, is suitable for topical 
applications (Agrawal et al., 2010; Chen et al., 2014; Patel et al., 2012; Souza et al., 
2011). 
 
12 
 
Emulsifier can be small molecule surfactants, phospholipids or even macromolecules 
such as protein and polysaccharides. It is applied for dispersing and stabilizing lipid 
nanoparticles in aqueous medium. Polyoxyethylene sorbitan monooleate, which is 
known as Tween 80, is a non-ionic and non-toxic surfactant that presents in food and 
cosmetic products. Due to its properties, Tween 80 does not dramatically affect surface 
charge of lipid nanoparticle (Gonzalez-Mira et al., 2010; Keck et al., 2014; 
Teeranachaideekul et al., 2007; Üner et al., 2004). Lecithin which is an excellent 
lubricant, can be fully metabolized by the body. Its zwitterionic effect works well as a 
charge neutralizer, aids in modifying surface charge of lipid nanoparticle for specific 
application (Han et al., 2012; Jia et al., 2010; Luan et al., 2014; Zhang et al., 2008). 
 
2.1.2 Techniques applied in NLC’s preparation 
The approaches taken in preparation of NLC could dramatically affect its properties. 
Solid lipid and/or emulsifier is required to be in the molten state in order to produce 
homogenized formulation. In spite of that, labile materials should be prevented from 
high temperature and sometimes solvent is required for better encapsulation efficiency. 
The techniques that are usually employed in the preparation of NLC include hot and/or 
cold homogenization, ultrasonication, and emulsification-solvent evaporation method 
(Almeida and Souto, 2007; Ekambaram et al., 2012; Patidar et al., 2010; Wissing et al., 
2004). 
 
2.1.2.1 Hot and/or cold homogenization 
In hot homogenization method, the lipid and/or surfactant are first melted at a 
temperature of 5 to 10 °C higher than the melting point of the materials. The molten 
mixture is then mixed with aqueous phase at the same temperature, followed by 
homogenization at a high speed to disperse and subsequently reduce the size of lipid 
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droplet. The evenly dispersed droplets will then crystallized in cold environment to 
form lipid nanoparticles. Further reduction and more uniform particle size can be 
obtained by passing through homogenized pre-emulsion in a high pressure homogenizer 
(Araújo et al., 2012; Fan et al., 2014; Liu et al., 2007; Souto et al., 2004b; Üner et al., 
2005). In cold homogenization method, the preparation procedure is similar as hot 
homogenization method. The difference between the two preparation methods is that in 
cold homogenization method, hot molten is being cooled down and ground into lipid 
microparticle before being dispersed in cold aqueous phase and finally passed through 
the high pressure homogenizer (Dangi et al., 2011; Neupane et al., 2014). Nevertheless, 
hot homogenization method is preferred to produce small and uniform particle 
(Mukherjee et al., 2009). 
 
2.1.2.2 Ultrasonication 
In ultrasonication method, lipid components are first dissolved in organic solvent, 
followed by solvent evaporation to form a thin layer of lipid film. The lipid thin film is 
then hydrated in emulsifier supplemented aqueous phase, followed by some agitation to 
disperse the lipid thin film and thereby lipid particle is formed. In most cases, the 
agitation is achieved by homogenization, followed by ultrasonication to ensure that the 
particles are in uniform size (Brugè et al., 2013; Castelli et al., 2005; Cirri et al., 2012; 
Pinto et al., 2014; Puglia et al., 2008).  
 
2.1.2.3 Emulsification-solvent evaporation 
In emulsification-solvent evaporation method, lipid matrix is first solubilized in water 
immiscible solvent and then added into an emulsified aqueous medium. The solvent will 
undergo evaporation and nanoparticle dispersion is formed when the lipid gradually 
precipitated into the aqueous phase (Sadiq and Rassol, 2014; Trotta et al., 2003; 
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Varshosaz et al., 2014). This method is suitable for labile active ingredients as it is free 
from high temperature heating. 
 
2.1.3 Advantages of NLC’s usage 
Lipid nanoparticle could enhance loading and encapsulation efficiency, improve active 
ingredient’s stability, allow deeper skin penetration and increase skin hydration. The 
imperfect amorphous structure of NLC gives more room for the accommodation of 
active ingredients than perfect structured SLN (Pople and Singh, 2011; Souto et al., 
2004a). Quercetin loaded NLC showed a higher encapsulation efficiency and loading 
capacity as compared to SLN (Aditya et al., 2014). Apart from that, lipid nanoparticle 
could encapsulate various types of active ingredients including coenzyme Q10 (Pardeike 
and Müller, 2007), psoralen (Fang et al., 2008), retinoic acid (Castro et al., 2009), 
flurbiprofen (Gonzalez-Mira et al., 2010), itraconazole (Pardeike et al., 2011), curcumin 
(Puglia et al., 2012), miconazole (Mendes et al., 2013), artemether (Nnamani et al., 
2014) and recombinant human epidermal growth factor (Gainza et al., 2015). Lipid 
nanoparticle could also protect labile active ingredient from oxidation and degradation 
by reducing its contact with the external environment (Puglia et al., 2014). The work 
done by Junyaprasert et al. (2009) showed that Q10 loaded NLC has better particle size, 
zeta potential and higher Q10 remained after one year storage as compared to 
nanoemulsion. Besides that, the amount of phenylethyl resorcinol loaded in NLC 
reduced by 1.3% only even though it was exposed to natural daylight for a period of 90 
days (Fan et al., 2014). 
 
Lipid nanoparticle helps to enhance active ingredient’s penetration, prevent skin 
dehydration and reduce adverse effect. Penetration enhancement is attributed by its 
lipophilic nature whereby lipid nanoparticle can partition into the skin layer more 
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efficiently. Glyceryl behenate/capric caprylic triglyceride genistein loaded NLC favours 
deeper skin layer penetration as compared to glyceryl behenate genistein loaded SLN 
because the fluidity of liquid lipid eases the penetration process (Andrade et al., 2014). 
Idebenone loaded NLC improved the permeation of active ingredient in guinea pig’s 
skin as compared to nanoemulsion and oil solution (Li and Ge, 2012). This was further 
supported by the work done by Schwarz et al. (2013), whereby Q10 with smaller particle 
size could penetrate into the deeper skin layer and it gave a higher penetration rate as 
compared to those with larger particle size.  
 
The occlusion effect of NLC is achieved by the formation of lipid thin film on top of the 
skin after the application of the formulation. Lipid thin film helps to repair and prevent 
water loss from the skin. In a comparison study done by Pardeike et al. (2010), it 
showed that Cutanova Nanorepair Q10 cream which consists of NLC has better skin 
hydration effect as compared to NLC free cream. Other than that, application of NLC-
silver complex on mild to medium severe atopic dermatitis patient not only hydrates the 
skin but also prevents the growth of bacteria which worsen the condition of atopic 
dermatitis (Keck et al., 2014).  
 
In hazardous prevention, molecular oxybenzone which presents in sunscreen, was 
shown to have a slower release rate by 50% in lipid nanoparticles as compared to 
similar size emulsion. Thus, amount of oxybenzone which accumulated on the skin 
could be reduced yet prolonged sun protection factor was achieved (Wissing and Müller, 
2002). Celecoxib loaded NLC can be modulated to achieve prolonged release of the 
active ingredients for the lessening of pain and inflammation that caused by rheumatoid 
arthritis, thus reduced the frequency of application of medicine (Joshi and Patravale, 
2008). 
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2.2 Liposome 
Liposome is a small spherical vesicle which composed of one or more lipid bilayer 
surrounding an aqueous inner core. This enables liposome to encapsulate both 
hydrophobic and hydrophilic active ingredients. The hydrophobic components are 
usually embedded in the lipid core while the hydrophilic components are entrapped in 
the aqueous interior, hence forming a protection layer for labile active ingredients from 
external environment (Immordino et al., 2006). That being the case, liposome is used as 
a carrier to encapsulate small molecules, peptides, hormones, genetic materials, 
antibiotics and anticancer agents (Chang and Yeh, 2012).  
 
Liposome can be classified into different categories based on their structural parameters 
and components for applications. Depending on the lamellar layer, liposome is 
structurally grouped as unilamellar and multilamellar vesicles (MLV). Unilamellar 
vesicles consist of single phospholipid bilayer while multilamellar vesicle has onion-
liked arrangements. Based on their size, unilamellar vesicle can be further categorized 
into small unilamellar vesicle (SUV), medium unilamellar vesicle (MUV) and large 
unilamellar vesicle (LUV) with size around 20-40 nm, 40-80 nm and 100-1000 nm 
respectively (Akbarzadeh et al., 2013). Depending on its components for application, 
liposomes can be either conventional liposome, long circulatory liposome, fusogenic 
liposome, pH sensitive liposome, cationic liposome or immuno-liposome. 
 
2.2.1 Surface modified liposome 
Conventional liposome is the most basic liposome that made up of neutral or negatively 
charged phospholipids and cholesterol. Diacylglyceride such as phosphatidyl choline 
(lecithin), phosphatidyl ethanolamine (cephalin), phosphatidyl serine or phosphatidyl 
inositol is the commonly used phospholipids (Mansoori et al., 2010). In order to 
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enhance the rigidity of lipid bilayer (Sulkowski et al., 2005) and provide signal 
transduction (Chattopadhyay and Paila, 2007), cholesterol is often added. Despite that, 
conventional liposome is recognized as an exogenous substance, thus it gets eliminated 
by the reticuloendothelial system of the body (Maruyama, 2011). As a result, stealth 
liposome or long circulatory liposome is being introduced.  
 
Stealth liposome has longer circulation time as a consequence of increase surface 
hydrophilicity and hindrance of negative surface charge by materials coated on 
liposome (Allen and Martin, 2004). Stearic stabilization is achieved when the coated 
PEG attracts water, in turn reduces both the adsorption of opsonins and recognition of 
liposome by MPS (Ishida et al., 2006; Yang et al., 2007). Doxorubicin encapsulated 
PEGylated liposome which marketed as Caelyx or Doxil, was introduced for cancer 
treatment (Ishida and Kiwada, 2008). Polysaccharide, O-palmitoylscleroglucan 
anchored liposome showed improved stability as compared to conventional liposome 
when being suspended in simulated gastric fluid and bile salt solutions (Carafa et al., 
2006). 
 
Fusogenic liposome is a liposome coated with Sendai virus envelope glycoproteins, 
either by natural or synthetic lipid for targeted delivery (Nicolosi et al., 2015). It can 
efficiently fuses through plasma membrane to deliver nucleotides and/or proteins 
(Kunisawa et al., 2005) and protects siRNA from degradation (Auguste et al., 2008). 
Fusogenic lipsosome was being shown to success in facilitating siRNA endosomal 
escape and enhancing gene silencing (Hatakeyama et al., 2009).  
 
 
18 
 
Immuno-liposomes formed when monoclonal or polyclonal antibodies are attached on 
the surface of liposomes for cell specific targeting (Park et al., 2004). Transmembrane 
glycoprotein, human epidermal growth factor receptor-2 (HER2) which over-expressed 
in breast cancer cells, serves as a receptor for recombinant humanized monoclonal anti-
HER2 antibody, Herceptin. When Herceptin is bound to liposomes, targeted delivery of 
immune-liposome to breast cancer cells could be achieved (Yang et al., 2007; Barrajón-
Catalán et al., 2010).  
 
pH sensitive liposome is designed to undergo acid-triggered destabilization and promote 
the release of active ingredients into cytosol (Sudimack et al., 2002; Torchilin, 2011). It 
is usually composed of dioleoylphosphatidylethanolamine (DOPE) with cholesteryl 
hemisuccinate (CHEMS) or oleic acid. In acidic condition, the lipids become partially 
protonated and lose its negative charge, attributed to the loss of bilayer structure’s 
stability by electrostatic repulsion (Cho et al., 2009; Ishida et al., 2006). Gemcitabine 
encapsulated pH sensitive liposome significantly increases cell apoptosis of non-small 
cell lung cancer as compared to free gemcitabine (Kim et al., 2009).  
 
Cationic liposome is widely explored as a mediator for proteins, peptides and DNA into 
cell. Cationic lipid including 3-(N-(N’,N’-dimethylaminoethane) carbomyl) cholesterol 
(DC-Chol), 1,2-dioleyl-3-trimethylammonium-propane (DOTAP), and 
dimethyldioctadecylammonium bromide (DDAB), with low immunogenicity and 
toxicity, has high potential for targeted delivery (Inoh et al., 2013; Maitani et al., 2007; 
Yan et al., 2007; Zhuang et al., 2012). Cationic liposome which forms a complex with 
siRNA, could enhance its cellular uptake as a consequence of electrostatic interaction 
between the complex and plasma membrane (Tagami et al., 2012). In a recent research 
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done by Saengkrit et al. (2014), curcumin loaded cationic liposome was shown to have 
improved surface charge by DDAB, thus enhanced the effect for cervical cancer therapy.  
 
2.2.2 Preparation of liposome 
Liposome can be easily prepared via dry lipid membrane technique. This was done by 
drying the dissolved lipid components from organic solvent followed by dispersing the 
dried lipid in aqueous media. The more specific preparation methods such as physical 
dispersion, solvent dispersion and detergent solubilisation were introduced.  
 
2.2.2.1 Physical dispersion 
Physical dispersion method can be carried out by sonication, membrane extrusion, 
micro-emulsification or freeze-thawing of liposomes. In sonication, bath sonicator or 
probe sonicator is employed to reduce the particle size of liposomes (Ćurić et al., 2013; 
Jiang et al., 2015). In membrane extrusion, liposome was passed through a membrane 
filter with specific pore size. Those with larger particle size will either retain on the 
upper part of the membrane or fuse through the membrane to form liposome with 
smaller particle size (Franzen et al., 2011; Nguyen et al., 2013). Micro-emulsification is 
executed under a high pressure micro fluidizer. The emulsified sample is brought to 
collide at a high velocity to produce liposomes with narrow particle size distribution 
(Lajunen et al., 2014; Tang et al., 2013). In freeze-thawing method, opposite result is 
achieved. During liposome’s rupture and reformation, small vesicles are formed within 
a larger vesicle. Hence, this method could increase the encapsulation efficiency of 
active ingredients (Guo et al., 2011; Xu et al., 2012). 
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2.2.2.2 Solvent dispersion  
In solvent dispersion method, the lipids are dissolved in ethanol or ether, followed by 
injection of the solution in aqueous phase which contains active materials (Meure et al., 
2008). In ethanol injection, ethanol dissolved lipids are rapidly injected into aqueous 
medium using fine needle. Ethanol is diluted while lipids is dispersed in aqueous phase 
to form liposomes (Justo and Moraes, 2011; Padamwar and Pokharkar, 2006). On the 
other hand, ether injection requires slower injection of water immiscible solvent into 
aqueous phase at vaporizing temperature of the solvent (Guan et al., 2012; Pham et al., 
2006). By using the solvent dispersion method, large scale of liposomes could be 
produced without degrading and oxidizing the lipids (Charcosset et al., 2014). 
 
2.2.2.3 Detergent solubilisation 
In detergent solubilisation method, liposome is formed through self-assembly of lipid-
detergent mixture. This method involved bilayer solubilisation by detergent from low to 
high concentration until critical micelle concentration (CMC) is reached. Below CMC, 
detergent molecules exist as free molecule in the solution. Gradual increase of 
detergent’s concentration in solution forms lamellar layer or known as detergent 
containing bilayer. When the concentration of detergent is further increased until it 
reaches CMC, lamellar layer undergoes dissolution and assembles into spherical vesicle 
known as lipid-detergent mixed micelle (Lichtenberg et al., 2013a; Lichtenberg et al., 
2013b). This method is applied in octylglucoside mediated solubilisation and 
reconstruction into unilamellar vesicle that composed of lipids extracted from E.coli 
membranes (Krylova et al., 2010). 
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2.2.3 Interaction of liposome with the body 
Liposome has the potential as a delivery carrier, owing to its features of specific 
targeting through surface modification, regulating distribution by liposomal size, 
prolonged release depending on the composition and protecting active ingredients from 
degradation and preventing body from adverse effects.  
 
During inflammation or presence of tumor, vascular pathophysiology would have some 
structural changes. The defect in blood vessel however enable the accumulation of small 
particle size materials in the interstitial space by fusing through endothelial cell and 
accumulating more particles in tumor tissue than normal cell. This phenomenon is also 
known as enhanced permeability and retention (EPR) effect (Danhier et al., 2010). Thus, 
liposome which undergoes surface modification, can retain in the bloodstream for a 
longer period without being phagocytized by macrophages. This modification could 
enhance the chance of liposome to fuse passively and accumulate at the targeted site 
(Nakano et al., 2008). Active targeting involves ligands that attached on liposome, bind 
specifically to receptor on the targeted cell (Noble et al., 2014). Active targeting of 
peptide ligand PH1 towards Tie2 receptor is proven when cisplatin loaded liposome 
down-regulates Tie2 which is linked to angiogenesis in cancer cell (Mai et al., 2009).  
 
The active ingredients’ release rate can be regulated depending on the surface 
composition of liposome. PEG coated liposome has prolonged circulation time in the 
body (Elbayoumi and Torchilin, 2008; Ishida et al., 2007; Kim et al., 2009). Sometimes, 
we could enhance the release of active ingredients by providing an acidic environment 
to pH sensitive liposome. DOPE liposome coated with acid labile PEG conjugated vinyl 
ether lipids was destabilized, thus induced release of calcein (Shin et al., 2003). 
Additionally, enhancement in doxorubicin release was being demonstrated in 
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thermosensitive liposomes that attached to poly(N-isopropylacrylamide-co-acrylamide) 
and PEG (Han et al., 2006). Targeted delivery of liposomes involves the mechanism of 
receptor mediated internalization whereby ligands targeted liposomes can deliver high 
amount of drugs to the targeted sites (Sapra and Allen, 2003). This is proven by 
Adibhatla et al. (2005) in phase III stoke clinical trials whereby cytidine-5’-
diphosphocholine (CDP-choline) loaded liposome has a better reduction in infarction as 
compared to free CDP-choline with equivalent dose.  
 
The size of liposome and active ingredients affect the therapeutic efficacy whereby 
small molecule drug loaded liposomes have better retention at active sites (Mirahmadi 
et al., 2010). It is plausibly related to the capability of liposomes to accumulate at the 
fiber network of tumors while free active ingredients can be easily diffused away and 
metabolized by the body. Epigallocatechin (EGCG) and catechin encapsulated liposome 
have higher local retention in basal cell carcinomas for the treatment of skin disorders 
(Fang et al., 2006).  
 
Liposome has a good protection layer to preserve labile active ingredients (Kim et al., 
2013; Kulkarni et al., 2011). In the work done by Coimbra et al. (2011), resveratrol 
which is prone to cis-trans isomerization under light, exhibits photostability property 
when being encapsulated in liposome’s lipid bilayer while carvacol disodium phosphate 
has a high loading efficiency in the aqueous core. Apart from small molecules, synthetic 
peptide which is bound with DNAhsp65 for loading into cationic liposome, functions as 
gene vaccine for therapeutic effects against diseases like tuberculosis (Rosada et al., 
2012). 
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Even though liposome has many benefits for application, but side effects might arise 
from potent active ingredients, thereby limits its usage and duration taken for 
therapeutic (Fang et al., 2001; Koudelka and Turánek, 2012). Acute and chronic 
cardiotoxicity were observed in breast cancer patients when being treated with 
anthracycline but there was a reduction of side effect when anthracycline was 
encapsulated in PEGylated liposomes (Jurcut et al., 2008). Reduction in adverse effect 
was also proven in the treatment of hepatic fibrosis, whereby interferon-γ (IFN-γ) 
liposome with prolonged release rate and targeted delivery towards hepatic stellate cell 
could enhance anti-fibrotic effects, thereby decreased the expression of ubiquitous 
receptor (Li et al., 2012). Apart from that, reduction of effective therapeutic dose could 
as well reduce the possible side effect. Decrease in toxicity is being observed in 
liposome complex encapsulated with amphotericin B for the treatment of leishmaniasis 
(Daftarian et al., 2013). 
 
2.3 Water-in-oil microemulsion 
Emulsion is a dispersion of two immiscible liquid of oil and water which stabilized by 
surfactants at the oil-water interface. It can be classified as microemulsion, 
nanoemulsion or macroemulsion. Microemulsion appear to be translucent or clear with 
a particle size less than 100 nm, nanoemulsion has a particle size up to 200 nm while 
macroemulsion is generally larger than 500 nm. Microemulsions are typically 
thermodynamically stable. Nevertheless, microemulsion’s formation is not necessarily 
spontaneous but it requires an input of external energy. On the other hand, 
nanoemulsion and macroemulsion which require high energy input either by sonication 
or homogenization are considered kinetically stable yet have the tendency to phase 
separate (Kogan and Garti, 2006; Lawrence and Rees, 2000; Okur et al., 2011; Yuan et 
al., 2006). Based on Winsor’s classification, microemulsion which fluctuates 
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dynamically can be structurally divided into Winsor type I, oil-in-water microemulsion; 
Winsor type II, water-in-oil microemulsion; Winsor type III, bicontinuous middle-phase 
microemulsion and Winsor type IV, single phase micellar solution (Eastoe, 2005). In 
oil-in-water microemulsion, globular-liked oil droplets are dispersed in aqueous 
continuous phase while opposite scenario happens in water-in-oil microemulsion. 
Currently, marketed products in the form of microemulsion or self-dispersing lipid 
formulation include Neoral
®
 (cyclosporin A for immunosuppressant); Aptivus
®
, 
Norvir
®
 and Fortovase
®
 (consist of tipranavir, ritonavir and saquinavir respectively 
works as protease inhibitor in HIV therapy) (Kalepu et al., 2013; Muzaffar et al., 2013).  
 
2.3.1 Compositions of microemulsion 
Microemulsion is made up of aqueous, oil, surfactant and co-surfactant. The selection of 
oil, surfactant and co-surfactant is limited to those which are non-toxic and non-irritant. 
Oil could protect the skin from dehydration (Telofski et al., 2012) and act as a 
penetration enhancer across epidermis (Wang et al., 2007). In most formulations, 
medium chain mono- and di-glyceride extracted from plant and animal is used as the 
excipients. In most cases naturally found plant-based oil such as almond oil, olive oil 
and jojoba oil is more preferable owing to its topical and oral benefits. Almond oil has 
numerous health and beauty benefits as it elevates high-density lipoproteins and serves 
as a natural emollient for skin rejuvenation (Ahmad, 2010). Olive oil helps to minimize 
the chances of persistent skin condition such as psoriasis, acne and eczema (Viola and 
Viola, 2009). On the other hand, Urpi-Sarda et al. (2012) proved that daily intake of 
olive oil helps to reduce the inflammatory biomarker such as interleukin-6, C-reactive 
protein and chemokine which is related to atherosclerosis. Jojoba oil which has similar 
chemical constituents as human sebum, helps to retain moisture without clogging the 
pores and has excellent oxidative stability (Sandha and Swami, 2009).  
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As an emulsifying agent, surfactants affect the structure of microemulsion by changing 
its molecular structure packing parameter. The critical packing parameter (v/aolc) of less 
than 1, favours oil-in-water micelle; equals to 1, favours bilayer vesicle; while more 
than 1, favours water-in-oil inverted micelle (Figure 2.2). It is classified into different 
classes namely non-ionic, anionic, cationic and amphoteric depending on the 
surfactant’s head group composition. Non-ionic surfactant does not carry charge while 
the other three surfactants are negatively, positively and oppositely charged respectively. 
Non-ionic surfactant such as sorbitan monooleate and polyoxyethylene sorbitan fatty 
acid ester is the preferred surfactant as it is non-toxic, non-irritant, biodegradable, stable 
towards changes of pH and ionic ingredients (Rowe et al., 2009). 
 
 
Figure 2.2:  Effect of surfactant packing parameters on the structure of microemulsion. The packing 
parameter of a surfactant is affected by the area of hydrophilic head group (ao), length of 
hydrophobic tail (lc) and the volume of the surfactant’s tail (v). The larger the value of 
packing parameters, the structure will be more prone to the formation of water-in-oil 
microemulsion. 
 
In order to improve the wetting ability, co-surfactants such as ethanol and propylene 
glycol were usually added in the formulation. Co-surfactants enhance the solubilisation 
process by forming flexible interfacial film (Kreilgaard, 2002; Morozowich and Gao, 
2009), reducing interfacial tension via increment of interface fluidity (Sripriya et al., 
2007; Zhang et al., 2012) and enhancing permeability capacity of active ingredients for 
delivery (Ahmad et al., 2014; Tsai et al., 2010). 
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2.3.2 Preparation of microemulsion 
The microemulsion is prepared either through phase titration or phase inversion 
temperature method. Several parameters such as temperature, types of oil, volume 
fraction of the droplets (φ) and molar ratio (R) of water to surfactant will affect the types 
of microemulsion being prepared. This can be evaluated by monitoring the density, 
viscosity and conductivity of the samples when those parameters are being manipulated 
during the preparation of microemulsion.  
 
In phase titration method, phase diagram is constructed in order to determine the region 
of microemulsion formation in the presence of oil, aqueous and surfactant phase. The 
three components are varied at different percentages to make up 100% of ingredients in 
either v/v or w/w ratio. The mixture is agitated for complete mixing and the phase is 
determined through visual observation. Only those with clear, single phase solution are 
labelled as microemulsion thence being marked in the phase diagram to form a 
microemulsion region. In this preparation, the selection of oil type selected is crucial as 
increment of chain length will produce more positive curvature as the penetration of the 
surfactant tails will decrease relatively (Oldfield, 1994).  
 
In phase inversion method, water-in-oil microemulsion is inverted into oil-in-water 
microemulsion or vice versa due to changes of temperature or continuous phase at the 
optimum surfactant concentration. If it is due to temperature changes, then inversion of 
oil-in-water microemulsion into water-in-oil microemulsion will depend on the cloud 
point of the surfactant in the mixture. It corresponds to temperature changes of 
surfactant’s hydrophilic-hydrophobic characteristics, whereby hydrophilic head group 
was dehydrated during heating (Ontiveros et al., 2014). On the other hand, changes of 
continuous phase can also cause phase inversion which was attributed by dilution. It 
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was observed that water-in-oil microemulsion loaded peptide for enhanced intestinal 
delivery slowly formed inverted oil-in-water microemulsion when the sample 
undergone a series of dilution with water up to 250-fold dilution (Liu et al., 2013). 
 
2.3.3 Advantages of microemulsion application 
Microemulsion gained more attention as compared to other emulsions as it helped to 
enhance drug solubility, better thermodynamic stability, ease in scale up and higher 
drug permeability (Chen et al., 2004; Okur et al., 2014). Thus, this system is widely 
used in transdermal, oral, nasal and ocular delivery. It was shown that curcumin loaded 
water-in-oil microemulsion has better transdermal permeation as compared to micellar 
and surfactant-oil mixture (Sintov, 2015). When being treated orally, the symptoms of 
enhancement in pharmacological activity and no sign of intestinal mucosa damage were 
observed in rats when they were treated with multiple doses of earthworm fibrinolytic 
enzyme loaded water-in-oil microemulsion (Cheng et al., 2008). The uses of 
microemulsion in the management of epilepsy through transnasal delivery is a 
breakthrough when carbamazepine loaded microemulsion with mucoadhesive not only 
displayed a better mucoadhesive effect and permeation rate but also free from nasal 
ciliotoxicity (Patel et al., 2013). Besides that, voriconazole with broad range antifungal 
properties has better corneal permeation and drug accumulation when being loaded in 
oil-in-water microemulsion for ocular delivery than only active ingredient itself (Kumar 
and Sinha, 2014). 
 
Active ingredients solubilisation in microemulsion is subject to the partition ability of 
active ingredients into the oil and aqueous phase. In water-in-oil miroemulsion, it 
depends on the ability of active ingredients to dissolve in the aqueous phase (Porter et 
al., 2008). Microemulsion with particle size which is less than 100 nm could enhance 
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permeability of active ingredients, thereby increasing its bioavailability in the system. In 
a comparison between microemulsion and tablet formulation, the results proved that the 
former has 12-fold higher bioavailability of saquinavir than the latter (Hosny and 
Hassan, 2014). The absorption rate could be improved by selecting lipids with similar 
properties as biological membrane, whereby phospholipids enhanced the permeability 
of poorly soluble active ingredients (Wu et al., 2014). Another emerging finding is the 
use of skin penetrating peptide (SPP) such as poly-arginine, dermis localizing peptide 
(DLP) and linear peptide-12mer (LP-12) to act as a penetration enhancer for topical 
delivery. The peptide acts as the mediator between the active ingredients and the keratin 
present in the stratum corneum (Chen et al., 2015; Kumar et al., 2015).  
 
The stability of the active ingredients in a delivery vehicle is highly dependent on its 
initial concentration, partition phase, and amount of external stimuli such as oxygen, 
light, pH, salt and temperature. In an experiment conducted by Špiclin et al. (2001), it 
showed that in the presence of oxygen, hydrophilic sodium ascorbyl phosphate is stable 
in water-in-oil microemulsion whereby 95% of active ingredients being remained after 
2 months of storage. The protection layer can be enchanced by forming a double layer 
microemulsion whereby the initial microemulsion was coated with another layer of 
component. Lycopene loaded double layer microemulsion has better stability than 
single layer microemulsion when the formulation was challenged by the changes in pH, 
salt and temperature (Shi et al., 2015). 
 
Apart from that, microemulsion is easy to scale up. The step of warming up an oil-in-
water microemulsion sometimes was being selected as the initial step to synthesize SLN 
with a monodispersed distribution (Marengo et al., 2000). This enables researcher to 
overcome the shortage in the up-scaling during preparation of SLN or NLC 
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(Mojahedian et al., 2013). It benefits the manufacturers due to the factors of cost 
effective, energy saving and ease in preparation. 
 
2.4 Polymeric nanocarrier 
Polymeric carrier as delivery vehicle has captured the attention of many researchers as it 
is biocompatible, biodegradable, cost effective and wide application. The polymeric 
material includes natural or synthetic polymers such as polylactic acid, 
polyvinylpyrrolidones, polysaccharides, proteins and peptides (Gong et al., 2011; 
Kaneda et al., 2004; van Zutphen and Reedijk, 2005). Depending on their structure and 
composition, they can be classified into hydrogel particle, filled hydrogel particle, 
biopolymeric particle, inclusion complexes and polyelectrolyte complexes for different 
functional performance (Hamidi et al., 2008; Hamman, 2010; Joye and McClements, 
2014). Among the polymeric material, polysaccharides are still the most favourable as 
they are abundantly found from natural sources and feasible for modification. 
 
2.4.1 Polysaccharide based nanoparticles 
Polysaccharides are composed of long chains homogeneous monosaccharide or 
heterogeneous copolymer units linked by glycosidic bonds. Naturally found 
polysaccharides usually originate from plants, algae, microbes and animals while 
synthetic polysaccharides are derived from naturally found polysaccharides. Among the 
naturally found polysaccharides, plant sources include cellulose, pectin, amylose; algae 
sources include alginate, carrageenan, fucoidan; microbe sources include xanthan gum, 
dextran, pullulan while animal sources include chitosan, heparin, chondroitin (Giri et al., 
2012; Linhardt and Liu, 2012; Liu et al., 2008; Szu et al., 2014). On the other hand, 
synthetic polysaccharide can be hydroxypropyl cellulose, methyl cellulose, 
hydroxypropylmethyl cellulose, N-trimethyl chitosan (Alves and Mano, 2008; Fettaka 
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et al., 2011). These polysaccharides with different chemical compositions or reactive 
groups serve as the main sources for synthesis of polysaccharide based nanoparticles. 
Negatively charged sodium alginate forms calcium alginate nanoparticles in the 
presence of positively charged calcium ions (Sugiura et al., 2005). When β-D-glucan is 
crosslinked with sodium tripolyphosphate, nanoparticles with anti-fungal properties 
were being synthesised (Anusuya and Sathiyabama, 2014).  
 
2.4.1.1 Chitosan 
Chitosan is a linear aminopolysaccharide consisting of N-acetyl-D-glucosamine and D-
glucosamine linked randomly by β-(1, 4) glycosidic bonds. This semi-crystalline 
polysaccharide is partially deacetylated derivative of chitin, found in crustacean shells 
such as crabs and shrimps (Patel et al., 2010; Tiyaboonchai, 2013). The crystallinity of 
chitosan is affected by the degree of deacetylated chitosan. Nevertheless, maximum 
crystallinity appears in 0% of deacetylation of chitin and minimum crystallinity in 100% 
of deacetylation of chitosan. The commercially available chitosan usually have 50 to 90% 
degree of deacetylation. Chitosan with high molecular weight is insoluble in neutral and 
alkaline conditions but soluble in mild acidic conditions. This is caused by protonation 
of free amino groups in the presence of acids (Suh and Matthew, 2000). Even so, 
chitosan can be soluble in water in the circumstances of low molecular weight or high 
degree of deacetylation of chitosan for different application (Malmo et al., 2012; Tan 
and Misran, 2013). Chitosan which is positively charged reacts more responsive 
towards anionic materials to form ionic complexes. Owing to its pH dependent 
properties, chitosan nanoparticles is stable in acidic pH while adhesion and penetration 
is enhanced in alkaline pH (Makhlof et al., 2011). 
 
31 
 
2.4.1.2 Carrageenan 
Carrageenan is extracted from algae of class Rhodophyta (red algae) using water or 
alkaline water followed by alcohol precipitation. It is abundantly found in the genus of 
Chondrus, Eucheuma and Kappaphycus and classified into kappa (κ), iota (ι) and 
lambda (λ) carrageenan. These linear polysaccharides which linked by glycosidic bonds 
are composed of galactose and/or anhydrogalactose units. The major dissimilarity 
among those carrageenans is their negatively charged sulphated ester group. κ-
carrageenan, ι-carrageenan and λ-carrageenan have one, two and three sulphated ester 
groups respectively. λ-carrageenan with three sulphated ester groups dissolve easily in 
hot and cold water but do not form gel while the other two carrageenans which are 
soluble at temperature higher than 60 ˚C or in the presence of sodium salt, form gel 
easily in the presence of gelling cations. As a consequence, carrageenan is a good 
excipient for gel formulation, suspension stabilizer, thickening agent in food and 
cosmeceutical products and suitable as controlled and sustained release delivery carrier. 
Mimicked release of methylene blue carrageenan hydrogel in gastrointestinal tract was 
shown to be minimized in the stomach and improved in the intestine (Hezaveh and 
Muhamad, 2012).  
 
2.4.2 Synthesis of polysaccharide nanoparticle 
Polysaccharide nanoparticles can be synthesized mainly by covalent crosslinking, ionic 
cross-linking, polyelectrolyte complexation or self-assembly of hydrophobically 
modified polysaccharide.  
 
In cross-link method, cross-linker or condensing agent such as glutaraldehyde is 
required to connect the polysaccharide chains. Nevertheless, many researchers limit the 
usage of glutaraldehyde because of its toxicity that could induces reduction in cell 
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viability (Gan and Wang, 2007). In most cases, biocompatible dicarboxylic acid such as 
malic acid, succinic acid and citric acid are much preferred as the cross-linker. The 
rationale in cross-linking depends on the condensation of amino group of 
polysaccharide with aldehyde or carboxylic group of the cross-linker (Wang et al., 
2011). Cross-linking particle is stable and less likely to degrade (Banerjee et al., 2002). 
The encapsulation of dextran-doxorubicin conjugate in chitosan nanoparticle by 
covalent linker has enhanced therapeutic effects and increased the survival rate of 
cancer patients (Mitra et al., 2001).  
 
Ionic cross-link depends on the interaction between charged functional group present in 
polysaccharide and small ionic molecules. Chitosan, guar gum and hydroxyethyl 
cellulose are positively charged while alginate, hyaluronic acid and carrageenan are 
negatively charged. In the presence of small anion molecule of tripolyphosphate (TPP) 
or cations of calcium ions, cross-linking occurs naturally in the presence of 
polysaccharide. Negatively charged TPP reacts with positively charged chitosan, 
forming particles for gene and small molecule delivery (Berger et al., 2004; Gan et al., 
2005; Ko et al., 2002; Luo et al., 2010). Calcium as divalent cations, co-precipitate with 
carrageenan to form biodegradable and non-toxic porous nanocomposite for bone tissue 
engineering (Daniel-da-Silva et al., 2007).  
 
In polyelectrolyte complexation, the mechanism is through intermolecular electrostatic 
interaction whereby positively charged polysaccharides react with negatively charged 
polymeric molecules (Xu et al., 2005). Since biocompatibility is one of the concern, 
chitosan with positively charged amino group could act as the natural polysaccharide 
(Luo and Wang, 2014; Wang et al., 2011). Chitosan can freely interact with negatively 
charged polysaccharides, peptides and other polyelectrolytes. The ratio of two 
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oppositely charged polysaccharides, pH and temperature can affect the properties of the 
complexes prepared (Kim et al., 2004). pH sensitive carboxymethyl Konjac 
glucomannan-chitosan beads which entrapped protein has site specific bioactive for 
delivery (Du et al., 2006). Chitosan interacts with pectin to form porous scaffold, which 
is suitable for tissue regeneration application (Coimbra et al., 2011). 
 
Polysaccharides’ self-assembly occurs when segments of hydrophilic part are modified 
with hydrophobic part to form amphiphilic polysaccharides. At the moment when 
amphiphilic polysaccharides come into contact with aqueous, they will aggregate 
spontaneously to form micelle or nanoparticles. This is ascribed to intra- and/or 
intermolecular hydrophobic interaction whereby hydrophobic segment aggregates to 
form inner core surrounded by hydrophilic segments. Thus, it is suitable for the 
entrapment of hydrophobic molecules (Liu et al., 2005; Park et al., 2006; Wang et al., 
2007). Hydrophobically modified glycol chitosan nanoparticles derived from glycol 
chitosan with 5β-cholanic acid has enhanced the distribution in whole cells through 
endocytic pathways as compared to unmodified glycol chitosan nanoparticle for gene 
delivery (Nam et al., 2009; Yoo et al., 2005). 
 
2.4.3 Polymeric nanoparticle for active ingredients delivery 
Chitosan is a natural wound healing accelerator which promotes granulation and 
organization of cell through activation of inflammatory cells such as 
polymorphonuclear leukocytes (PMN), macrophage and fibroblast (Paul and Sharma, 
2004; Ueno et al., 2001). Chitosan has higher wound break strength and collagenases 
activity as compared to chitin as those with higher deacetylation degree has more 
activated fibroblast that would promote wound healing (Minagawa et al., 2007). 
Antimicrobial effects of chitosan with molecular weight below 300 kDa contribute to 
34 
 
wound healing by inhibiting the growth of Staphylococcus aureus on the skin (Zheng 
and Zhu, 2003). In addition, chitosan with antacid and anti-ulcerative properties could 
prevent drug irritation in the stomach (Gupta and Kumar, 2000). On the other hand, 
carrageenan has antiviral effects on various types of enveloped viruses. This is owing to 
the presence of sulphated group in carrageenan which interferes the interaction of virus 
glycoprotein with the cell (Pujol et al., 2002). Apart from that, carrageenan also 
possesses anticoagulant and antioxidant properties (de Araújo et al., 2013; Yermak et 
al., 2012). 
 
The polysaccharides are capable for active ingredient’s encapsulation and delivery 
depending on bioactive molecule-biopolymer binding, protein-polysaccharide 
interactions, pH dependent solubility differences, self-assembling, crosslinking and 
hydrophobic modification (Bilensoy et al., 2009; Nagpal et al., 2010; Patel and Velikov, 
2011). Chitosan nanoparticles loaded with insulin for lung delivery showed high protein 
loading capacity by reaching a maximum of 80% and showing fast release of insulin 
from the microspheres (Grenha et al., 2005). Depending on the molecular weight and 
degree of deacetylation, chitosan which successfully binds with oppositely charged 
DNA are capable for gene transfection in the HEK 293 cell (Lavertu et al., 2006). 
Cross-linking of carrageenan and epichlorohydrin was shown to have controlled release 
properties as it affects the particles’ swelling ratio (Keppeler et al., 2009). 
 
In mucosal delivery, the physical barrier made up of epithelium greatly reduces the 
permeability of active ingredients. This problem can be overcome by bioadhesive 
features possessed by chitosan (Pan et al., 2002). Positively charged chitosan can easily 
adhere to negatively charged mucosal surface and transiently opens the tight junction 
between epithelial cells. This significantly prolongs the residence time of chitosan 
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nanoparticles and enhances the absorption of active ingredients across epithelium 
(Bravo-Osuna et al., 2007; Dudhani and Kosaraju, 2010; Martinac et al., 2005). 
Nanoparticles synthesized by complexation of chitosan and DNA are shown to be a 
promising vehicle for oral gene delivery due to its mucoadhesive properties (Plapied et 
al., 2010). Besides that, in a comparison between both chitosan and Carbopol hydrogels 
to act as wound dressing, chitosan hydrogel has twice the retention of active ingredients 
on the skin as compared to Carbopol hydrogel, hence suggesting that the chitosan 
formulation has better bioadhesive properties (Hurler and Škalko-Basnet, 2012). 
 
κ-carrageenan-chitosan nanoparticles have high potential to be exploited specific site 
targeting through EPR effects. The biocompatible nanoparticle with suitable particle 
size can pass through the blood vessel and accumulate at the tumor with ease. Cisplatin-
loaded glycol chitosan nanoparticle showed antitumor efficacy in tumor-bearing mice 
(Kim et al., 2008), revealing the possibilities of κ-carrageenan-chitosan nanoparticles 
towards the treatment of tumor. Apart from EPR effect, we can also make the most out 
of tumor and inflammatory cell which has lower endosomal pH and slightly higher 
temperature as compared to normal cell. Acidic or hyperthermic condition induced 
disassembly of stimuli sensitive nanoparticle, thus enhanced the release of entrapped 
active ingredients. This is a result of protonation of amine group or changes in lowering 
critical solution temperature (LCST) of nanoparticles (Fan et al., 2008; Jin et al., 2012; 
Nogueira et al., 2013; Wang and Zhang, 2012). Paclitaxel loaded pH sensitive 
nanoparticle has enhanced cytotoxicity in tumor-bearing mice as compared to those 
cells in normal pH (Li et al., 2009). On top of that, doxorubicin hydrogel containing 
chitosan-doxorubicin conjugates and Pluronic with physical gelation above LCST, has 
better in vivo therapeutic effect on solid tumor as compared to free doxorubicin (Cho et 
al., 2009). Targeted delivery can be achieved through specific targeting receptor and 
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ligand-bearing nanoparticles or degradation by specific microorganisms (Park et al., 
2010). Folate receptor which is mostly absent in normal cell was being found plentifully 
in malignant tumors, especially ovarian carcinoma (Zhao and Lee, 2004). This special 
characteristic promotes folic acid to bind specifically on the receptor for higher active 
ingredients’ delivery (Mansouri et al., 2006). On the other hand, microflora which are 
found abundantly in intestine can specifically breakdown the glycosidic bond of 
polysaccharides for colon-specific targeted delivery (Gupta et al., 2012; Hejazi and 
Amiji, 2003). 
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CHAPTER 3: MATERIALS AND METHODS 
Lipid nanoparticle, liposome, water-in-oil microemulsion and κ-carrageenan-chitosan 
nanoparticle with its own special features, could aid in the dissolution and permeation 
of active ingredients via improved encapsulation and controlled release. Thus, each 
system was individually prepared, optimized and characterized for its physicochemical 
properties. Depending on the system, the characterizations might include particle size, 
zeta potential, morphology, thermal properties, pH, electrical conductivity, viscosity 
and/or infrared spectrophotometry. From the obtained results of characterization, the 
most suitable formulation for each system was being encapsulated with active 
ingredients of different solubility in water and evaluated for their release profile.  
 
3.1 Materials 
Arachidic acid, linoleic acid, linolenic acid, oleic acid, polyoxyethylene sorbitan 
monopalmitate (Tween 40), polyoxyethylene sorbitan monostearate (Tween 60), 
polyoxyethylene sorbitan monooleate (Tween 80), polyoxyethylene sorbitan trioleate 
(Tween 85), sorbitan  monooleate (Span 80), L-ascorbic acid, caffeine, lidocaine, 
phosphate buffered tablet, sodium hydroxide pellet, boric acid, sodium tetraborate, and 
phosphotungstic acid were purchased from Sigma-Aldrich, USA. Erucic acid, sorbitan 
monopalmitate (Span 40) and κ-carrageenan were obtained from Fluka, Switzerland. 
Chitosan was from Acros, Belgium. Glacial acetic acid, hydrochloric acid and sodium 
acetate trihydrate were from Merck, USA. Extra virgin olive oil was purchased from 
Laleli, Turkey. All materials were used without any further purification. 
 
Deionized water with resistivity of 18.2 mS cm
-1
 was dispensed from Barnstead 
NANOpure
®
 Diamond
TM
 (Thermo Scientific, USA). U-shaped clear capillary cell was 
from Malvern, UK. Quartz clear cell was from Thermoscientific, USA. DSC hermetic 
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pan was from TA instruments, USA. The dialysis membrane was from DIANORM 
GmbH, Germany. Last but not least, the 400 mesh TEM copper grid was from Electron 
Microscopy Sciences, USA. 
 
3.2 Preparation of delivery carriers 
3.2.1 Preparation of NLC 
For the preparation of NLC, arachidic acid and erucic acid were both selected as solid 
lipid, oleic acid as liquid lipid while Span 40 as emulsifier. Fatty acids were being 
selected as the lipid components, owing to the fact that they can be metabolized by the 
body and thus being served as energy resources. Apart from that, it is cost effective, 
biocompatible and can be found abundantly either in natural or synthetic forms. On the 
other hand, Span 40 is non-toxic and biocompatible. 
 
NLC was prepared by employment of hot homogenization technique. Mixture of fatty 
acids, being listed as in Table 3.1 and Span 40 was weighed at ratio 8:2 (w/w) and 
melted at 90 ˚C.  Deionized water (2 ml) of same temperature was then added into the 
mixture and homogenized using T25 basic homogenizer (IKA, Germany) for 10 
minutes with the speed of 15000 rpm. Lastly, the homogenized sample was immediately 
poured into ice cooled deionized water to form NLC.  
 
Table 3.1: Compositions of lipid components for the preparation of NLC 
Sample 
Fatty Acids (weight percentage) 
Arachidic acid Oleic acid Erucic acid 
NLC 1 80 10 10 
NLC 2 70 20 10 
NLC 3 60 30 10 
NLC 4 50 40 10 
NLC 5 40 50 10 
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3.2.2 Preparation of liposome 
The C18 unsaturated fatty acid liposome with a final concentration of 10 mM was 
prepared via thin film hydration method. Depending on their respective molecular 
weight of unsaturated fatty acids, oleic acid (13.9 mg), linoleic acid (14.0 mg) and 
linolenic acid (14.1 mg) were all weighed and dissolved in 1 ml of chloroform. The 
solvent was then evaporated by using a rotary evaporator (Rotavapor
®
 R-114, BÜCHI
®
, 
Switzerland) at 45.0 ˚C to form a thin layer of lipid film on the wall of round bottom 
flask. The lipid thin film was rehydrated with 2 ml of 50 mM borate buffer pH 8.6 and 
dispersed using a bath sonicator (JEIO Tech, Korea) for a minute to form liposome. The 
pH of the liposomal solution was being adjusted to pH 8.6 by using 50 mM sodium 
hydroxide or hydrochloric acid, then topped up to a final volume of 5 ml in a volumetric 
flask.  
 
3.2.3 Preparation of water-in-oil microemulsion  
The preparation of water-in-oil microemulsion was done by mixing a specific amount of 
deionized water, olive oil and surfactant with mild agitation. In our case, Span 80 was 
mixed individually at a ratio of 1:1 with various types of Tween surfactants, namely 
Tween 40, 60, 80 and 85. The mixed surfactant was then added with olive oil and 
deionized water. The mixture was agitated using a small orbital shaker (MS1 shaker, 
IKA
®
, Germany) at 1000 rpm for a minute. 
 
In order to identify the region of microemulsion formation, ternary phase diagram was 
constructed. With a total weight of 2 g (w/w), 5% of it was contributed by mixed 
surfactant while the remaining 95% was added with olive oil and deionized water. As an 
example, when 5% of mixed surfactant was present in the formulation, it was topped up 
with 1% of deionized water and 94% of olive oil (w/w), followed by agitation. In a 
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similar amount of surfactant, the procedure was repeated with an increased amount of 
deionized water and a decreased amount of olive oil proportionally, at a 1% difference 
to make up a total of 100% (w/w). The process was then repeated by varying the 
amount of the mixed surfactant with a 5% increment until the surfactant amount finally 
reached 95%. Visual observation of a single phase clear solution indicated the 
microemulsion phase and was marked on the ternary phase diagram. The prepared 
microemulsion was being labelled according to the mixed surfactant that presents in the 
formulation, i.e. Span 80 and Tween 40 was identified as ST40, Span 80 and Tween 60 
as ST60, Span 80 and Tween 80 as ST80, as well as Span 80 and Tween 85 as ST85. 
 
3.2.4 Preparation of κ-carrageenan-chitosan nanoparticle 
κ-carrageenan-chitosan nanoparticle was prepared by formation of polyelectrolyte 
complex (PEC) of two oppositely charged polymer. With this, 100 mg of chitosan and 
100 mg of κ-carrageenan were dispersed individually and being stirred overnight in 
sodium acetate buffer which ranged from pH 3 to pH 6 for a final concentration of 1 mg 
ml
-1
 (w/v) in both solutions. For the κ-carrageenan solution, it was heated at 60 ˚C for 
10 minutes before being stirred overnight. Then, the solutions with same pH were 
mixed at a speed of 1000 rpm for 30 minutes by using MR Hei-Standard magnetic 
stirrer (Heidolph, Schwabach, Germany) in various ratios of 1:5, 2:4, 3:3, 4:2, and 5:1 
(v/v) respectively to form κ-carrageenan-chitosan nanoparticle to a final volume of 30 
ml. The mixture was centrifuged at 14,000 rpm for an hour by using centrifuge 
(Velocity 18R Refrigerated Centrifuge, Dynamica Scientific Ltd., United Kingdom) to 
collect the κ-carrageenan-chitosan nanoparticle and subsequently, the pellet was dried in 
vacuum oven (SHEL LAB vacuum oven, Sheldon Manufacturing Inc., USA) with a 
vacuum control of 25 inch Hg. The yield of each combination was then weighed. 
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3.3 Principle and characterization of delivery carriers 
3.3.1 Particle size and zeta potential 
The Malvern Zetasizer Nano Series performs size measurement by using the technique 
known as dynamic light scattering (DLS). DLS measures Brownian motion and relates 
it to the size of particle. It was done by illuminating the particles with a laser and 
analyzing the intensity fluctuations in the scattered light. When the particle was 
illuminated, it will show bright and dark area. The bright area appears when the light 
passes through unscattered, whereas the dark area appears when the light was scattered 
and detected by the detector. The relationship between the size of a particle and its 
speed which due to Brownian motion, is defined in the Stroke-Einstein equation as in 
Eq. 1, 
 
Dt =  
kT
6πηRh
 Eq. 1 
 
where Dt is the translational diffusion constant (m
2
 s
-1
), k is the Boltzmann constant 
(1.3806 × 10
-23
 m
2
 kg s
-2
 K
-1
), T is the absolute temperature (K), π is the ratio of a 
circle’s circumference to its diameter of approximately 3.1416, η is the viscosity of the 
solution (kg m
-1
 s
-1
), and Rh is the hydrodynamic radius of particle (m). 
 
Thus, if a large particle is being measured, it moves slowly and the intensity of scattered 
light fluctuates slowly. On the contrary, a smaller particle will have a faster motion 
whereby the intensity of scattered light will fluctuate more vigorously. Other than the 
size of the measured particle, changes in the viscosity or temperature could also affect 
the frequency of collision and as a result, it affects the coalescent. At higher viscosity or 
lower temperature, frequency of collision will be lower, thus coalescent will be 
relatively lower for a stable formulation. 
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In the measurement of zeta potential, firstly we need to determine the electrophoretic 
mobility of a sample by performing an electrophoresis to evaluate the velocity of the 
particle using laser Doppler velocimetry (LDV). Then, the zeta potential was calculated 
by substitution of the obtained electrophoretic mobility in the Henry equation (Eq. 2), 
 
UE =  
2εζ f(κa)
3η
 Eq. 2 
 
where UE is the electrophoretic mobility (m
2
 s
-1 
V
-1
), ε is the dielectric constant, ζ is the 
zeta potential (mV), η is the viscosity of the solution (kg m-1 s-1), and f(κa) is Henry’s 
function with a value of 1.5 for polar solvent as Smoluchowski approximation or 1.0 for 
non-polar solvent as Huckel approximation. 
 
The magnitude of zeta potential gives an indication of the potential stability of a 
colloidal system. If the particles in suspension have a large negative or positive zeta 
potential, they will tend to repel each other and have lesser tendency to flocculate. On 
the other hand, if the particles have low zeta potential values, it is easier for the particle 
to come together and flocculate. In most cases, particles with a zeta potential which is 
either more positive than +30 mV or more negative than -30 mV are considered stable. 
 
In the experiment, the mean z-average, size distribution, zeta potential and the standard 
deviation of the sample were obtained using the Malvern Zetasizer Nano Series (Nano 
ZS, Malvern Instruments, UK) performed at 25.0 ˚C. The sample was loaded in a quartz 
clear cell with a 1 cm path length for measurement of particle size and particle size 
distribution while U-shaped gold pleated folded capillary cell was used for zeta 
potential determination. The particle size was measured in triplicates whereby each 
measurement consists of 12 runs on the sample and the average particle size was 
obtained. All prepared delivery carriers were determined for their particle size, particle 
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distribution and zeta potential except for water-in-oil microemulsion which was 
evaluated only for particle size and particle distribution. The dispersing medium for 
NLC, liposome and κ-carrageenan-chitosan nanoparticle is water while for water-in-oil 
microemulsion is olive oil. 
 
3.3.2 Transmission electron microscopy (TEM) 
In TEM, the source of illumination is a beam of high velocity electrons accelerated 
under vacuum, focused by condenser lens onto the specimen. The loss and scattering of 
electrons by the individual part of the structure, formed the image seen on the 
micrograph after passed through several objective lenses until they reached the 
fluorescence screen. The wavelength of the propagating electrons at a given accelerating 
voltage can be determined by an equation derived from the deBroglie equation that 
shown as Eq. 3, 
 
λ = 
h
√2mqV
 Eq. 3 
 
where λ is the wavelength of an electron (m), h is the Planck’s constant of 6.6261 × 10-
34
 J s, m is the electron mass with 9.1094 × 10
-31
 kg, q is the electron charge of 1.6022 × 
10
-19
 C, V is the accelerating voltage (eV). From calculation, TEM with accelerating 
voltage of 120 kV and 200 kV, have electrons’ wavelength of 3.54 pm and 2.74 pm 
respectively. Hence, the resolution of the image increases when the accelerating voltage 
of the electron beam increases. 
 
The morphology of prepared delivery carrier via negative-staining method, was 
observed under a TEM (Carl Zeiss LIBRA
® 
120, Germany or JOEL JEM-2100F, Japan), 
conducted at the School of Biological Sciences, University Sains Malaysia (USM, 
Malaysia) or Physics Department, University Malaya (UM, Malaysia) respectively. A 
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drop of sample solution was positioned on a 400 mesh carbon coated copper grid and 
left for a timeframe between 30 seconds to 3 minutes. The excess sample solution was 
removed by using filter paper and being air-dried for a minute. The sample on the grid 
was then added with one drop of 1% phosphotungstic acid solution and left for few 
minutes to stain the sample. Any excess solution was dabbed with filter paper and air-
dried prior to being visualized under the TEM. The acceleration voltage was applied at 
120 kV for Carl Zeiss LIBRA
®
 120 and 200 kV for JOEL JEM-2100F. 
 
3.3.3 Differential scanning calorimetry (DSC) 
DSC monitors heat effects which associated with phase transitions and chemical 
reactions as a function of temperature. It records the difference in heat flow to the 
sample and reference at the same temperature. Since the DSC was performed at constant 
pressure, the heat flow is equivalent to enthalpy changes. The heat flow difference 
between the sample and reference was shown as Eq. 4 below, 
 
∆
dH
dt
= ( 
dH
dt
)
sample
- ( 
dH
dt
)
reference
 Eq. 4 
 
where ∆ is the change of any changeable quantity, 
𝑑𝐻
𝑑𝑡
 is the heat flow (mW) of amount 
of heat supplied at given time. 
 
The heat flow difference can be either positive or negative. In an endothermic process 
such as dehydration, reduction and some decomposition of sample, heat is being 
absorbed thus the heat flow difference is positive. On the other hand, in an exothermic 
process such as crystallization, oxidation and some decomposition of sample, heat is 
being released thus the heat flow difference is negative. From the thermogram of heat 
45 
 
flow, the thermal profile such as onset temperature, peak temperature and melting 
enthalpy of samples can be analyzed and calculated. 
 
The thermal profile of samples was monitored by DSC Q20 (TA instruments, USA). 2 
to 3 mg of lipid nanoparticle was weighed in a 40 µl hermetic aluminium pan. The DSC 
analysis was performed with a scan rate of 5 ˚C per minute within a temperature range 
from 20 to 300 ˚C depending on the sample. An empty pan was used as the reference. 
The analysts were being repeated for 3 cycles. 
 
3.3.4 Critical vesicular concentration (CVC) 
The measurement of CVC depends on the effect of solute or monomer on the surface 
tension as stated in Gibbs adsorption isotherm, which was shown in Eq. 5,  
 
Γ = 
1
nRT
 (
δγ
δ ln C
) Eq. 5 
 
where Γ is the surface concentration (mol m-2), n is the number of mole (mol) which 
implies the mass of a substance to its relative mass, R is the gas constant of 8.3145 m
3
 
Pa K
-1
 mol
-1
, T is the absolute temperature (K), δ is the changes of any changeable 
quantity, γ is the surface tension (N m-1), and ln C is the natural logarithm for 
concentration of substance in bulk phase (mol m
-3
). 
 
Surface tension changes drastically with proportional to the changes of monomer when 
the concentration is prior to reach CVC. Despite that, after reaching CVC, the surface 
tension varies slightly towards the changes of monomer concentration or remains 
relatively constant. The point of inflection indicates the CVC of the solution. 
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In the experiment, the CVC of liposome was determined using tensiometer (K100, 
KRṺSS-GmbH, Germany) by measuring a series of liposomal solution ranged from 
0.017 to 6.74 mM. The solution was poured into a vessel and five measurements were 
taken using tensiometer by employing du Noüy ring method at 30.0 ˚C (Teo et al., 
2012). The mean surface tension of the solution was plotted against ln [fatty acid]. The 
minimum concentration required for the vesicle formation could be estimated from the 
inflection point obtained from the graph. 
 
3.3.5 FTIR 
The operation of FTIR is based on Michelson Interferometer whereby the light directed 
to beam splitter was half reflected while the other half was transmitted. The two beams 
with different optical paths will then reflected back to the beam splitter which causes 
constructive or destructive of particular frequency and transferred into signal which 
known as interferogram. Thus, FTIR operates based on the principle called Fourier 
transform with a mathematical expression as Eq. 6 whereby the interferogram was 
converted into a spectrum. 
 
F(ω)= ∫ f(x) eiωx dx
+∞
-∞
 Eq. 6 
 
where F(ω) is the spectrum, f(x) is the interferogram, ω is the angular frequency, and dx 
is the optical path difference. Since Fourier transform is a density function, the spectrum 
is obtained by integrating the interferogram. 
 
An infrared spectrum represents a fingerprint of a sample with absorption peaks which 
corresponds to the frequencies of vibrations between the bonds of the atoms which 
make up the material. For example, the absorption band of around 1680 – 1620 cm-1 and 
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3550 – 3200 cm-1 represents alkenyl C=C and phenol O-H stretch respectively. This 
showed that the infrared spectrum for each material is different from each other because 
of the uniqueness in the combination of atoms. Hence, FTIR is usually applied in 
qualitative analysis to identify the functional group that presents in a material. This 
method is quick, time saving, suitable for many types of sample and no external 
calibration required. 
 
The functional group of chitosan powder, κ-carrageenan powder, the mixture of 
chitosan with κ-carrageenan powder as well as dried κ-carrageenan-chitosan 
nanoparticle, all were being determined using FTIR (Perkin Elmer, USA). The FTIR 
spectra were recorded in the range of 4000 – 450 cm-1 with 16 scans at spectral 
resolution of 4 cm
-1
 (Rajaram and Natham, 2013). The spectrum of κ-carrageenan -
chitosan nanoparticle was compared with the spectrums of chitosan powder and κ-
carrageenan powder to identify the formation of new bonding in κ-carrageenan-chitosan 
nanoparticle. 
 
3.3.6 Swelling percentage 
The dried κ-carrageenan-chitosan nanoparticle was weighed and added with 5 ml of pH 
7.4 phosphate buffer. Then, at the time interval of 15 minutes, 30 minutes, 1 hour, 2 
hours, 4 hours, 6 hours, 12 hours and 24 hours, the swelled κ-carrageenan-chitosan 
nanoparticle was being weighed accordingly. The maximum swelling percentage of κ-
carrageenan-chitosan nanoparticle after 24 hours was calculated as Eq. 7, 
 
SP = 
a - b
b
 × 100% Eq. 7 
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where SP is the swelling percentage whereby the swelling properties of a particle is 
measured, a is the weight of swelled κ-carrageenan-chitosan nanoparticle (g), b is the 
weight of dried κ-carrageenan-chitosan nanoparticle (g).                    
       
3.3.7 pH 
The pH of a solution measures the degree of acidity or alkalinity relative to the 
ionization of water. It involves comparison of the potential of solutions with unknown 
[H
+
] to a known reference potential. pH meter converts the voltage ratio between a 
reference half-cell and a sensing half-cell to pH values. The changes in potential and 
detection of [H
+
] were represented by Nernst equation (Eq. 8), 
 
E = Er + (  
2.303RT
zF
) log (  
[H+]
u
 [H+]
i
) Eq. 8 
 
where E is the total potential difference (V), Er is the standard cell potential (V), R is 
the gas constant of 8.3145 J K
-1
 mol
-1
, T is the absolute temperature (K), z is the valence 
or charge of the ion, F is the Faraday’s constant of 9.65 × 104 C mol-1, [H+]u is the 
hydrogen ion concentration of measured sample (mol m
-3
), [H
+
]i is the hydrogen ion 
concentration of internal reference (mol m
-3
). 
 
The pH of prepared water-in-oil microemulsion, liposome, and buffer solution was 
measured using the S47-K SevenMulti™ dual meter pH/conductivity (Mettler Toledo, 
Switzerland). The pH probe is InLab
®
 Expert Pro electrode with a solid polymeric 
electrolyte. The measurement was carried out in three replicates. 
 
3.3.8 Conductivity 
Conductivity is the measurement of the ability of an electrolyte solution to conduct 
electricity. The principle of conductivity measurement determines the resistance of the 
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solution between two electrodes that separated by a fixed distance. Resistance is 
determined according to Ohm’s Law (Eq. 9) through the ratio of voltage to current of an 
object while the conductance is the reciprocal of resistance.  
 
G = 
1
R
= 
I
V
 Eq. 9 
 
where  G is the conductance (kg
-1
 m
-2
 s
3
 A
2 or Ω-1), R is the resistant (kg m2 s-3 A-2 or Ω), 
I is the current (A), V is the voltage (kg m
2
 s
-3
 A
-1 
or V). The standardized conductivity 
(S m
-1
) is obtained by multiplying the conductance with cell constant, whereby cell 
constant is the ratio of the distance between the electrodes to the area of the electrodes. 
 
Conductivity measurement is useful in the determination of the continuous phase of the 
prepared microemulsion. When aqueous solution is the continuous phase, the 
conductivity will be very much higher than that of water-in-oil microemulsion. This is 
due to the fact that aqueous is a better conductor than oil (Anjali et al., 2010). 
 
The conductivity of water-in-oil microemulsion was measured by using S47-K 
SevenMulti dual meter pH/conductivity (Mettler Toledo, Switzerland). The 
measurement was determined using InLab
®
 731 with four-graphite poles of a cell 
constant 0.57 cm
-1
. The measurement was carried out in three replicates. 
 
3.3.9 Viscosity 
Viscosity measures the flow ability of a material moving through surfaces. Fluids resist 
relative motion of layers with differing velocities within them, opposing changes in the 
initial formation, hence generating internal resistance to flow. A fluid showing high 
resistance to opposing flow is said to be thick or viscous while those having small 
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resistance to flow are thin or runny. The viscosity of a sample is defined by shear stress 
over shear rate as Eq. 10 below, 
 
η = 
τ
γ
 Eq. 10 
 
where η is the viscosity of the sample (Pa s), τ denotes the shear stress where amount of 
force applied to sample per unit area (Pa), and γ signifies the shear rate where velocity 
per unit height (s
-1
). 
 
Newtonian fluid is independent on the shear rate whereby the shear stress is 
proportional to shear strain rate. For non-Newtonian fluid, the viscosity is affected by 
the shear rate which causes the sample to be shear thickening or shear thinning.  
 
Viscosity of the prepared water-in-oil microemulsion was determined using a Bohlin 
Instruments Gemini advanced rheometer (Malvern, UK). The method used was from 
Basheer et al. (2013) with some modification. The measurement was performed at a 
controlled temperature of 25.0 ± 0.1 ˚C, using a 1˚/60 mm cone and plate geometry with 
a gap of 30 μm in a shear range of 0.1 - 100 s-1. The apparent viscosity of sample was 
recorded at a shear rate of 50 s
-1
. 
 
3.4 Loading efficiency, encapsulation efficiency and release profile of nanocarrier 
Based on the physicochemical characterization of prepared nanocarriers, formulation 
with the most desired properties was selected from each system for encapsulation or 
solubilisation of active ingredients, followed by active ingredients release using Franz 
diffusion cell. Depending on their solubility in water, the active ingredients selected 
were ascorbic acid, caffeine and lidocaine with decreasing hydrophilicity. Ascorbic acid, 
caffeine and lidocaine are grouped under Class I, II and III respectively under 
51 
 
biopharmaceutical classification system. Their chemical structure and properties were 
shown in Table 3.2. 
 
Table 3.2: Chemical structure and properties of active ingredients 
 Chemical structure 
Solubility in 
water 
Molecular 
Weight (g mol
-1
) 
Melting Point 
(˚C) 
Ascorbic Acid 
 
Freely 176.12 191 
Caffeine 
 
Sparingly 194.19 238 
Lidocaine 
 
Slightly 234.34 68.5 
 
 
3.4.1 Loading and encapsulation of active ingredients 
3.4.1.1 Preparation and evaluation of encapsulated NLC 
The active ingredients encapsulated NLC was prepared using the same method as 
unloaded NLC. The only difference in the preparation is that active ingredients were 
first dissolved in the medium where it was soluble. Thus, ascorbic acid was dissolved in 
water while caffeine and lidocaine were dissolved in lipid phase. The prepared sample 
was filtered through 0.2 μm nylon filter (Sartorius Stedim, Belgium) whereby the NLC 
will entrapped on donor part of the membrane while NLC-free clear filtrate was 
measured by Cary
®
 50 UV-Vis spectrophotometer (Varians, Agilent Technologies, 
USA) using two clear side quartz cuvette with 1 cm path length. 
 
3.4.1.2 Preparation and evaluation of encapsulated liposome 
The loading of active ingredients into fatty acid liposomes was prepared in a similar 
way as NLC whereby lidocaine and caffeine were individually dissolved together with 
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the lipid phase before subjected to solvent evaporation while ascorbic acid was added 
during the rehydration process. The encapsulated liposomal sample was centrifuged 
through 50 kDa molecular weight cut off (MWCO) vivaspin6 column (Sartorius Stedim, 
Belgium) at 1500 rpm for 15 minutes whereby unencapsulated active ingredients will be 
separated out while the liposome will be remained in the upper part of vivaspin6 
column. The unencapsulated active ingredient was measured by Cary
®
 50 UV-Vis 
spectrophotometer using two clear-sided quartz cuvette with 1 cm path length. 
 
3.4.1.3 Preparation and evaluation of water-in-oil microemulsion  
For loading of active ingredients in water-in-oil microemulsion, the active ingredients 
were first solubilized in deionized water before introduced in the mixture as aqueous 
phase. The amount of active ingredients was solubilized at optimum concentration of 
lidocaine in water of 3 mg ml
-1
 to standardize their amount in the formulation. 
 
3.4.1.4 Preparation and evaluation of encapsulated κ-carrageenan-chitosan 
nanoparticle 
During entrapment of active ingredients, the sample was prepared as unloaded κ-
carrageenan-chitosan nanoparticle except that the active ingredients were first dissolve 
in κ-carrageenan solution prior to mixing with chitosan solution. The mixtures were 
then centrifuged to collect the active ingredients loaded κ-carrageenan-chitosan 
nanoparticle while the supernatant was used to estimate the unloaded active ingredients 
by employing Cary
®
 50 UV-Vis spectrophotometer using two clear-sided quartz cuvette 
with 1 cm path length. 
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For all nanocarriers except water-in-oil microemulsion, the loading efficiency (Eq. 11) 
and encapsulation efficiency (Eq. 12) were being calculated as the equation below, 
 
LE = 
b - c
a
 × 100% 
 
Eq. 11 
EE = 
b - c
b
 × 100% 
Eq. 12 
 
where LE is the loading efficiency of the active ingredients (%), EE is the encapsulation 
efficiency of the active ingredients (%), a is the weight of NLC/ liposome/ κ-
carrageenan-chitosan nanoparticle (g), b is the total weight of active ingredients present 
in the formulation (g), c is the weight of unencapsulated active ingredients (g). 
 
3.4.2 Franz diffusion cell for active ingredient’s release profile 
A cumulative percentage of active ingredients’ release from delivery carrier was carried 
out at 37.0 ˚C for a period of 24 hours using the in-line Hanson MicroettePlus™ 
diffusion system (Hanson Research, USA). The diffusion system was equipped with a 
vertical clear glass diffusion cell of 0.9 cm orifice diameter, 1.9 ml donor volume and 4 
ml receptor volume. A dialysis membrane of 5000 Da molecular weight cut-off 
(MWCO) was soaked in the receptor medium for at least 12 hours prior to be mounted 
between the donor and receptor chamber. The donor chamber consisted of 500 μg active 
ingredients while the receptor chamber was filled with a pH 7.4 phosphate buffer 
solution. At predetermined time intervals of 0.5 hour, an hour, 2 hours and subsequent 2 
hours, the sample was automatically collected. The concentration of active ingredient in 
the collected sample was estimated by employing a Cary
®
 50 UV-Vis 
spectrophotometer, using a quartz cuvette with a 1 cm path length. The experiment was 
conducted for six replicates. 
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3.4.3 Kinetic models 
The drug release model was determined by fitting the results of cumulated release of 
active ingredients into the zero-order model, the first-order model, the Higuchi model, 
the Hixson-Crowell model and the Korsmeyer-Peppas model (Dash et al., 2010). 
 
3.4.3.1 Zero-order model 
Zero-order model is usually applied in describing the drug dissolution of several types 
of modified release pharmaceutical dosage forms in some transdermal systems. Apart 
from that, it is also suitable for the release of drug from matrix tablet with low soluble 
drugs in coated form and osmotic system. The dissolution of active ingredients can be 
represented by Eq. 13: 
 
Q0 - Qt = K0 t Eq. 13 
 
where Q0 is the initial amount of drug in the solution (g), Qt is the amount of drug 
dissolved in time t (g), K0 is the zero order release constant, and t is the time (s). In 
zero-order model, the graph is plotted as cumulative percentage released against time. 
 
3.4.3.2 First-order model 
First-order model is used to describe absorption and/or elimination of drugs which 
contain water soluble drug in porous matrices. It is presumed that the drug diffusion is 
in one direction and concentration dependent. The dissolution of active ingredients can 
be represented by Eq. 14: 
 
 
Log C = Log C0   - 
Kt
2.303
 Eq. 14 
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where  C is the concentration of drug at designated time (g L
-1
), C0 is the initial 
concentration of drug (g L
-1
), K is the first order rate constant, and t is the time (t). The 
slope is defined as 
K
2.303
. For first-order model, the graph was plotted as log of the 
remaining percentage release against time. 
 
3.4.3.3 Higuchi model 
Higuchi model is valid for all the time until the drug was totally depleted from the 
system. In most cases, it is applied for drug dissolution from several types of modified 
release pharmaceutical dosage forms, transdermal system and matrix tablet with water 
soluble drug. In this system, it is presumed that the initial drug concentration in the 
matrix is much higher than drug solubility; drug diffusion takes place only in one 
dimension; drug particles are much smaller than system thickness; matrix swelling and 
dissolution are negligible; drug diffusivity is constant and perfect sink conditions are 
always attained in the release. The dissolution of active ingredients can be represented 
by Eq. 15: 
 
Q = KH × t
1/2
 Eq. 15 
 
where Q is the amount of drug released in time t per unit area (g s
-1
 m
-2
), KH is the 
higuchi dissolution constant, and t is the time (s). In Higuchi model, the graph is plotted 
as the cumulative percentage release against the square root of time. 
    
3.4.3.4 Hixson-Crowell model 
Hixson-Crowell model fits best to pharmaceutical dosage in tablet form where the 
dissolution occurs in planes that are parallel to the drug surface if the tablet dimension 
diminishes proportionally, in such a manner that the initial geometrical form keeps 
constant all the time. The dissolution of active ingredients is represented by Eq. 16: 
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W0
1/3 - Wt
1/3 = Kt Eq. 16 
 
where W0 is the initial amount of drug in the pharmaceutical dosage form (g), Wt is the 
remaining amount of drug in pharmaceutical dosage form at time t (g), K is the constant 
incorporating the surface-volume relation, and t is the time (s). The graph of Hixson-
Crowell model is plotted as the cube root of drug percentage remaining against time. 
   
3.4.3.5 Korsmeyer-Peppas model 
Korsmeyer-Peppas model is applied to understand the release of drug from a polymeric 
system. The mechanisms considered in this model include diffusion of solvent into the 
polymeric system, swelling of polymeric system, formation of gel, diffusion of active 
ingredients out of the polymeric system and dissolution of the polymeric system’s 
matrix.  The dissolution of active ingredients is represented by Eq. 17: 
 
Mt
M∞
=Ktn Eq. 17 
 
Where t is the time (s), 
Mt
M∞
  is the fraction of drug released at time t, K is the release rate 
constant, n is the release exponent. In Korsmeyer-Peppas model, the graph is plotted as 
the log cumulative percentage release against log time. In spite of that, the mechanism is 
limited to the first 60% of drug release from the system. 
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CHAPTER 4: RESULTS AND DISCUSSION 
4.1 Physical characterization of delivery carriers 
Depending on the characteristics of the carrier system, the prepared samples were 
characterized to select the more suitable formulation from each system for active 
ingredients’ encapsulation and release. For NLC, particle size, zeta potential, 
morphology and thermal profile were evaluated. For liposome, particle size, zeta 
potential, morphology, CVC were determined. For water-in-oil microemulsion, particle 
size, morphology, viscosity, pH and conductivity were assessed. For κ-carrageenan-
chitosan nanoparticle, particle size, zeta potential, morphology, FTIR and swelling 
percentage were measured. 
 
4.1.1 Characterization of NLC 
The NLCs prepared by Span 40 and mixed fatty acids of arachidic acid, erucic acid and 
oleic acid, were evaluated for their particle size, zeta potential, thermal profile and 
morphology. In the formulations, erucic acid and Span 40 were unvaried ingredients 
while percentages of arachidic acid and oleic acid in mixed fatty acids were both 
decreased and increased by 10% respectively for each formulation. Thus, the evaluation 
of prepared NLC was being focused on the effect of varied ratio of solid and liquid 
lipids towards the stability of the formulations. The formulation which consists 80% of 
arachidic acid and 10% of oleic acid in the mixed fatty acids was named as NLC 1. The 
mixture was gradually varied until NLC 5 which consists 40% of arachidic acid and 50% 
of oleic acid in the mixed fatty acids. 
 
The particle size analysis of prepared NLC was shown to be affected by the amount of 
oleic acid presents in the formulation. From Figure 4.1, a gradual increase of oleic acid 
by 10% weight percentage of the lipid mixture in the formulation caused an apparent 
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increase in the particle size of the NLC when the formulation was evaluated on the first 
day. The changes in the particle size were observed for all NLC formulations when the 
stability of the NLC prepared was evaluated. It was shown that beyond Day 14
th
, the 
changes of the particle size reached maximum particle stability whereby there is none or 
minimum changes in particle size for the formulation prepared. In addition, the 
polydispersity index of the NLC which has a value of 0.22 for all NLC indicates that the 
formulation has a high tendency to be an unimodal distribution. The increase in particle 
size with respect to a higher amount of oleic acid in the formulation can be explained 
from the nature of oleic acid, which has an unsaturated double bond at C9-C10, formed 
a kink in the structure. As a result, it prevents the formation of compact and rigid NLC 
with smaller particle size. In addition, higher amount of liquid lipid in the formulation 
might also attribute to a more disordered crystalline structure which affects the particle 
size of the NLC (Sangsen et al., 2015).  
 
Figure 4.1: Changes in particle size of NLC samples prepared by using different fatty acid compositions 
for a storage period of 28 days at 30 ˚C. The symbols  = NLC 1,  = NLC 2,  = NLC 3,  
= NLC 4,  = NLC 5. 
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Besides particle size, on the first day after preparing the NLC, the zeta potential which 
fluctuate within -52 ± 3 mV for all NLC formulations showed no significant difference 
in the zeta potential (Figure 4.2). Nevertheless, the changes in zeta potential of the NLC 
has a similar pattern with the particle size, whereby it showed an overall a slight 
increase of zeta potential followed by stable zeta potential around -47 mV after Day 10
th
. 
The sample is defined as a stable dispersion if the measured zeta potential has a 
magnitude of more than positive or less than negative 30 mV. The stability of NLC is 
enhanced by the degree of electrostatic repulsion between the adjacent NLC particles 
with similar charged in the solution, thereby preventing the NLC particles from 
aggregation.  
 
Figure 4.2: Changes in zeta potential of NLC aqueous suspension with varied fatty acid compositions as 
a function storage time of 28 days at 30 ˚C. The symbols  = NLC 1,  = NLC 2,  = NLC 3, 
 = NLC 4,  = NLC 5. 
 
In addition, DSC analysis was performed on NLC sample in order to determine the heat 
gain or heat loss for a certain mass of sample with respect to time. The results may be 
affected by the physical or chemical changes of the sample. Thus, from the thermal 
parameters of onset temperature, peak temperature and melting enthalpy which obtained 
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from DSC curve, the structure of the sample can be predicted. The onset temperature is 
known as the melting point, peak temperature is the temperature at which maximum 
reaction rate occurs while melting enthalpy is calculated by the integration of the area 
above or below the baseline. These three parameters are highly affected by the 
compositions which present in the NLC. As a consequence, those with more liquid lipid 
have a lower onset temperature, peak temperature and enthalpy changes as compared to 
those with higher solid lipid content (Figure 4.3 and Table 4.1). 
 
The change in the thermal parameters on the NLC prepared is affected by the amount of 
oleic acid which made up the particle. Oleic acid, with the melting point of 13-14 ˚C, 
tends to melt at room temperature as compared to arachidic acid and erucic acid which 
have a melting point above 40 ˚C. On that account, a mixture with less oleic acid is 
expected to form a more rigid solid structure with higher crystallinity. Apart from that, 
the peaks of melting temperature broaden while the peak height gradually decreased 
when the amount of oleic acid was gradually increased. This indicates the loss in the 
crystallinity of NLC. 
 
Table 4.1: Thermal parameters of fatty acids based NLC 
 Onset Temperature, (˚C) Peak Temperature, (˚C) Melting Enthalpy, ΔH (J g-1) 
NLC 1 67.6 71.8 156.7 
NLC 2 65.4 70.5 144.9 
NLC 3 59.0 67.7 109.4 
NLC 4 53.2 65.9 67.82 
NLC 5 49.9 62.5 59.51 
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Figure 4.3: Differential scanning calorimetry thermogram of NLC. The experiment was performed from 
25 ˚C to 100 ˚C at a scan rate of 5 ˚C per minute. 
 
As a supplementary to the above results, three TEM micrographs as in Figure 4.4 
clearly showed the morphology of the NLC prepared. NLC 1 which has the least oleic 
acid, had particles which were more rounded and uniform in shape as in Figure 4.4(a). 
However, when about 20% more oleic acid was added into the formulation as compared 
to NLC 1, the shape of NLC 3 turned to be more elongated in shape as shown in Figure 
4.4(b). The shape of NLC 5 was further extended and the overall size is larger than 
those with lesser oleic acid as in Figure 4.4(c). The size result of TEM is in agreement 
with the particle size obtained from DLS measurement, whereby the ascending order of 
particle size is NLC 1 < NLC 3 < NLC 5. NLC with higher liquid lipid content might 
possess higher active ingredients’ encapsulation efficiency. Nevertheless, from the 
micrographs, it gave us an idea that NLC was unsuitable to have liquid lipid more than 
30% in the lipid components as the sample might form oil droplet apart from NLC. 
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(a) 
 
(b) 
 
(c) 
Figure 4.4:  TEM micrographs of NLC where (a) is NLC 1, (b) is NLC 3, and (c) is NLC 5. All 
micrographs were taken at 10, 000 × magnification using Carl Zeiss LIBRA
®
 120. 
 
As a summary, the evaluation of physical characteristics for NLC indicated that NLC 
with different fatty acids as lipid phase was successfully prepared. Among the NLC, 
NLC 3 exhibit the most desired properties of the nanoparticle, whereby the size is 
around 250 nm with a zeta potential of less than -45 mV. In addition, the TEM 
micrographs of NLC 3 showed to have an acceptable shape with no oil droplet formed 
as compared to those with higher oleic acid in the compositions. Besides that, thermal 
profile of NLC 3 with lower onset temperature than those with higher solid lipid, 
indicated that NLC 3 requires lesser energy for deformation of the NLC. This could 
enhance the release rate of active ingredients encapsulated NLC. Hence, NLC 3 was 
being selected for the encapsulation of active ingredients and prediction of release 
profile. 
 
4.1.2 Characterization of Liposome 
Liposomes prepared by using different types of C18 unsaturated fatty acids, namely 
oleic acid (C18:1), linoleic acid (C18:2), and linolenic acid (C18:3), were evaluated for 
their physical characteristics which include CVC by employing surface tensiometer, 
particle size and zeta potential by using zetasizer, followed by morphology with the use 
of TEM.  
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The CVC is the minimum concentration where vesicles formed. The surface tension of 
the solution was shown to decrease linearly as a function of fatty acid concentration 
until it reached the inflection point, followed by a plateau, even when the concentration 
of fatty acid was increased (Figure 4.5). This phenomenon can be explained by the 
Gibbs adsorption isotherm of the monolayer at the air-water interface. When the 
adsorption of free fatty acids at the air-water interface gradually increased, a dramatic 
reduction in surface tension was observed with small changes in the bulk phase 
concentration. At the point near to the CVC, the interface was at its maximum surface 
coverage, thus promoting aggregation of the fatty acids in the solution to form vesicles 
in order to reduce the high free energy. This was followed by a plateau in the surface 
tension when the surface access concentration was at its optimum (Eastoe, 2005; 
Treiner, 2006). 
 
Figure 4.5: Surface tension of fatty acids liposome solution with different concentrations evaluated at pH 
8.6 with a temperature of 30 ˚C.  = oleic acid,  = linoleic acid,  = linolenic acid. The 
arrow indicates the critical vesicular concentration of fatty acid liposomes. 
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From the CVC value estimated from the surface tension profile, it was observed that the 
prepared fatty acid liposomes had an increasing trend in their CVC values with respect 
to the degree of unsaturation in the fatty acids. Oleic acid, with only one double bond, 
had a CVC of 0.09 mM. Linoleic acid and linolenic acid, with additional one and two 
double bonds as compared to oleic acids, had CVC values that increased nearly twice 
and four folds to 0.16 mM and 0.41 mM respectively. This can be explained by the 
degree of unsaturation in the hydrocarbon chain of the fatty acid, which affects the 
polarity of the fatty acids. The effect of unsaturation towards the polarity of the 
hydrocarbon chain of fatty acids was shown by Nikolova-Damyanova (2009), whereby 
those with a higher degree of unsaturation were eluted at an earlier retention time in 
silver ion high performance liquid chromatography (HPLC). The increase in the polarity 
of the unsaturated hydrocarbon chain was due to the delocalization of π-electrons 
(Folmer, 2003). By reason of that, oleic acid, which has the least degree of unsaturation, 
is more hydrophobic as compared to linoleic acid and linolenic acid, thereby favouring 
the formation of vesicles through hydrophobic interaction, thus lowering the CVC value. 
A similar trend was also reported previously (Teo et al., 2011), which showed that the 
CVC value of a fatty acid is bond unsaturation-dependent. Despite that, the CVC values 
at pH 8.6 showed a lower CVC value compared to pH 9. The phenomenon is explained 
through the relationship between the pKa of the material and the pH of the prepared 
solution. Oleic acid, linoleic acid and linolenic acid have pKa of 9.85, 9.24 and 8.28 
respectively (Kanicky and Shah, 2002). At these pKa values, half of the fatty acid is in 
ionized form, while the other half is in unionized form. Hence at a pH that is higher than 
the pKa value, most of the fatty acids tend to be in ionized form as compared to those 
with a lower pH. That being the case, at pH 8.6, the amount of unionized fatty acid is 
higher as compared to those at pH 9.0, thereby favours the formation of vesicles due to 
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the ionic pair interaction between the ionized and non-ionized forms of fatty acids via 
lateral hydrogen bonding at lower pH (Apel et al., 2002; Fameau et al., 2014). 
 
Aside from CVC, particle size and zeta potential are also important parameters to 
evaluate the prepared liposome. The particle size of liposomes has been shown to be 
influenced by the degree of unsaturation of fatty acids, whereby those with more double 
bonds have a smaller particle size, as tabulated in Table 4.2.  
 
Table 4.2: Particle size, polydispersity index and zeta potential of fatty acid liposome and their stability 
for two weeks at 30 ˚C 
 Particle Size (nm)  Polydispersity Index  Zeta Potential (mV) 
Time (Day) 1
st
 7
th
 14
th
  1
st
 7
th
 14
th
  1
st
 7
th
 14
th
 
Oleic acid 
101.4 
(1.2) 
102.7 
(1.8) 
102.8 
(2.6) 
 0.28 
(0.02) 
0.28 
(0.03) 
0.30 
(0.02) 
 -104 
(3.5) 
-101 
(2.5) 
-105 
(3.8) 
Linoleic acid 
87.15 
(3.1) 
97.3 
(2.5) 
104.7 
(1.7) 
 0.31 
(0.03) 
0.32 
(0.03) 
0.27 
(0.02) 
 -101 
(2.8) 
-98.2 
(3.5) 
-94.7 
(2.1) 
Linolenic acid 
77.28 
(2.3) 
100.6 
(2.8) 
109.4 
(2.1) 
 0.42 
(0.03) 
0.37 
(0.02) 
0.30 
(0.02) 
 -99 
(4.3) 
-102 
(2.6) 
-97.5 
(3.2) 
The particle size, polydispersity index and zeta potential of fatty acid liposome is depending on their degree of unsaturation. Oleic 
acid liposome has a better stability as compared to linoleic and linolenic acid liposome. Upon two weeks storage, all the liposome 
has almost the same physical properties. The numbers in bracket indicate the standard deviation of the measurement obtained. 
 
This phenomenon is due to the fluidity of the fatty acid molecules in the presence of the 
double bonds. Linolenic acid, with three double bonds, has a higher bending flexibility 
could form a smaller liposome as compared to the other two fatty acids (Ishii and Nii, 
2014). However, oleic acid liposome was shown to be more stable as compared to the 
other fatty acids as there is apparently no change in the particle size and zeta potential 
whereas linoleic and linolenic acid liposomes have shown an increase in particle size 
which come to marginal change after Day 7
th
 due to the destabilization of high fluidity 
membrane. The hydrodynamic radius of the particles increased as a result of 
flocculation of the liposome particles. The polydispersity index of all the liposomes was 
shown to be between 0.25 and 0.45, indicating a broad range of particle distribution 
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among the vesicles. In addition, there is no drastic change in zeta potential of all the 
fatty acid liposomes after two weeks of storage. This was attributed by buffering effect 
between the buffer and electrolytes present in the solution, which might minimize the 
fluctuation of the zeta potential changes. 
 
The morphology of prepared liposome appeared to be rounded in shape but 
polydispersed in size when observed under TEM. On average, the diameter of the 
observed micrographs is slightly larger than DLS measurements, indicating that there 
might be structural collapse of the sample at a pressure of 3 × 10
-5
 Pa in the TEM 
chamber. Among the three samples, sample prepared by using oleic acid as in Figure 
4.6(a), showed to be rounded in shape with well-defined boundary than those prepared 
by linoleic acid and linolenic acid which presented in Figure 4.6(b) and Figure 4.6(c) 
respectively. Additionally, more unsaturation on the fatty acid chain gave a broader 
greyish shadow at the edge of the prepared samples. This suggested that oleic acid 
which presumably with better rigidity could stay intact as compared to the other two 
samples which smeared when exposed to vacuum pressure in TEM. Nevertheless, no 
aggregation was observed in this system.  
 
 
(a) 
 
(b) 
 
(c) 
Figure 4.6:  TEM micrographs of liposome where (a) represents oleic acid, (b) represents linoleic acid, 
and (c) represents linolenic acid liposome. For those micrographs, all were taken at 8,000 × 
magnification by using JOEL JEM-2100F. 
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As a summary, the physical characteristics of oleic acid liposome was shown to be 
superior than the other two types of fatty acid liposomes by having a particle size 
around 100 nm and high magnitude of zeta potential. Additionally, the TEM 
micrographs further confirmed that oleic acid liposomes are more rounded in shape. In 
addition to that, oleic acid which has lower CVC value, would ease the assembly and 
formation of vesicle in the bulk phase. Thus, oleic acid liposome was selected for the 
encapsulation of active ingredients and the release profile was determined.  
 
4.1.3 Characterization of water-in-oil microemulsion 
Water-in-oil microemulsion was prepared by mixing different compositions of water, 
olive oil, and mixed surfactants. At the initial stage, phase diagram was plotted to 
determine the region where the microemulsion could be found, followed by physical 
properties evaluations which included pH, conductivity, particle size, viscosity and 
morphology. 
 
The ternary phase diagram showed that the prepared water-in-oil microemulsion, 
formed a region at low water content in the presence of surfactant ranging between 20% 
and 90% (w/w) as shown in Figure 4.7. When the samples were prepared using Span 80 
with Tween 85 mixed surfactant, the microemulsion phase was found within a narrower 
region between 20% and 50% as shown in Figure 4.7(d). The region was found broader 
and ranging between 30% and 90% when mixed surfactant of Span 80 and Tween 40, 
60 or 80 were used as shown in Figure 4.7(a), Figure 4.7(b) and Figure 4.7(c) 
respectively. The result was found similar to the work done by Syed and Peh (2014) 
whereby microemulsion forms at higher surfactant region. This is probably due to the 
effect of hydrophilic and lipophilic properties of the surfactant. Despite the fact that the 
Tween surfactants have a similar headgroup, Tween 85 is more hydrophobic than the 
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other three Tween surfactants. This is attributed by the presence of three lipophilic tails 
in Tween 85 compared to the other three Tween surfactants which has only one 
lipophilic tail. Thus, the microemulsion stabilized by Span 80 and Tween 85 surfactants 
is restricted to a smaller region as compared to the other microemulsions. As a result, 
surfactant range between 30% and 50% for mixed surfactant compositions is the most 
suitable composition range that appears to fit all the surfactant combinations. In order to 
accommodate a higher amount of water solubilised active ingredients, a higher water 
phase is crucial when selecting the formulation. For that reason, a mixture of 40% 
surfactant, 56% olive oil and 4% deionized water was selected for further 
characterization and discussion. 
 
  
 
(a) (b) 
  
(c) (d) 
 
Figure 4.7: Ternary phase diagram of microemulsion prepared by olive oil, water and mixed surfactants 
of Span 80 with various types of Tween surfactants, namely (a) Tween 40, (b) Tween 60, (c) 
Tween 80 and (d) Tween 85. The shadowed region indicates the presence of microemulsion. 
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A formulation with a suitable pH range is crucial as it will affect the efficacy of active 
ingredients’ delivery and might cause irritation to the skin if the pH is unsuitable. In this 
perspective, the most preferred condition for topical applications would be a neutral pH. 
The results showed that ST85 and ST80 have the lowest and highest pH of 6.25 and 
7.36 respectively among those microemulsions while both ST40 and ST60 have a pH 
close to 7 (Table 4.3). The variation in pH obtained is plausibly attributed to the 
hydroxyl ions adsorption at the non-ionic polar headgroup of the surfactants, which 
arisen from the interaction of hydrogen bond at the ether-oxygen of the polyoxyethylene 
chain, hence resulting in an overall negatively charged surface (Liu et al., 2006; 
Marinova et al., 1996). Tween 85 which has three lipophilic tails is more hydrophobic 
attributed by the shielding of the polyoxyethylene chain. Thenceforth the adsorption of 
hydroxyl ions on Tween 85 is less preferable (Hsu and Nacu, 2003) as compared to the 
other three Tween surfactants. As a consequence, the magnitude of pH reduction in 
ST85 is comparatively higher as compared to the other three microemulsions. 
Additionally, Tween 40, Tween 60 and Tween 80, which all consist of single aliphatic 
tail, have hydroxyl value around 90-105, 81-96 and 65-80, respectively, indicate the 
amount of free sorbitol-derived cyclic ethers present in the surfactants. If the hydroxyl 
value of the sample is higher, the acid value is also comparatively higher. This is in 
agreement with the results, whereby the pH is in the order of ST40 < ST60 < ST80 
(Rowe et al., 2009; Wakita et al., 2014). Hence, ST40, ST60 and ST80 are more 
preferable for topical applications. The results from the conductivity analysis of the 
microemulsions showed that conductivity values are mostly less than 0.05 mS cm
-1
, 
which indicate that the microemulsions formed are all water-in-oil microemulsions. The 
microemulsion that  stabilized by a non-ionic surfactant, has a negligible charge, thus 
prevents or slows down the migration of droplets, which results in low conductivity 
(Bumajdad and Eastoe, 2004). In addition, it has also been reported that a formulation 
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which is made up of deionized water and olive oil, other than the non-ionic surfactant, 
also resisted the electrical conductivity (Anjali et al., 2010). 
 
Table 4.3:  Physical properties of water-in-oil microemulsions prepared with different types of Tween 
surfactants measured at 30 ˚C 
 pH Conductivity (mS cm
-1
) Particle Size (nm) 
ST40 6.81 ± 0.05 < 0.05 29.98 ± 1.0 
ST60 6.99 ± 0.03 < 0.05 30.81 ± 1.8 
ST80 7.36 ± 0.06 < 0.05 22.42 ± 0.9 
ST85 6.25 ± 0.06 << 0.05 16.86 ± 0.7 
 
The particle size of the water-in-oil microemulsion is directly determined by the 
packing parameter of the surfactants. Since all four microemulsions were being selected 
at certain compositions, they have similar compositions in their formulations, except for 
Tween surfactants. Therefore, the Tween series is the main contributor for a different 
packing parameter, which will be further discussed on their effect towards the changes 
of the particle size. Tween surfactants consist of hydrophilic polyethoxylated sorbitan 
headgroups, will orientate inwards to the aqueous phase, and hydrophobic fatty acid tail 
facing outwards to the oil phase during the formation of the water-in-oil microemulsion. 
Since all Tween surfactants have a similar headgroup but a different aliphatic 
hydrocarbon tail, the particle size of the microemulsion depended on the packing 
parameter of the surfactant’s aliphatic hydrocarbon tail. ST40 (C16:0) and ST60 (C18:0) 
which have saturated fatty acid tails, give a marginal increase in particle size when the 
hydrocarbon chain length increases. When unsaturated Tween 80 (ST80, C18:1) was 
introduced into the system, the particle size was reduced to around 23 nm, as compared 
to ST60 which has a particle size around 31 nm. ST80 has the same hydrocarbon chain 
length as ST60 but it is different in the degree of saturation, whereby the former has one 
double bond at C9-C10. The double bond in Tween 80 gives a certain degree of bending 
on the aliphatic hydrocarbon tail, thus changes the packing parameter of the surfactant 
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from a cone shape to rod shape. The rod shape surfactant favours the water-in-oil 
microemulsion as compared to the cone shape. When the aliphatic hydrocarbon tail was 
increased to three unsaturated tails (ST85, C183:1), the particle size was further reduced 
to around 17 nm. The reduction in particle size is attributed to those three unsaturated 
hydrocarbon tails of Tween 85, aids the formation of inverted cone shape which is the 
most preferable shape for water-in-oil microemulsion. Apart from the aliphatic 
hydrocarbon tails, HLB value of surfactants would also affect the particle size of 
microemulsion. The surfactant with a lower HLB (ST85) value tends to possess a less 
hydrated headgroup as compared to the one with a higher HLB value. The headgroup 
which does not swell significantly can produce a more compact arrangement and gives a 
smaller particle size. Besides that, the particle size result is in correlation with viscosity, 
whereby those with small particle sizes have low viscosity. This is true as smaller 
particles will flow much easier as compared to those larger particles when shearing is 
applied. Microemulsions with polydispersity index around 0.15 suggest that the 
microemulsion is uniform in size. 
 
On the other hand, the viscosity of a microemulsion is being affected by the types and 
concentrations of surfactants, oils, water, co-solvents, ionic strength, pH and 
temperature of the formulation (Lawrence and Rees, 2000). In general application, 
microemulsion with low viscosity is easy to apply on the skin. Nevertheless, its high 
fluidity makes it difficult to be controlled during application. Microemulsion with a 
higher viscosity is the most preferred condition for application in this system. Most 
microemulsion’s studies exhibited Newtonian fluid because a change in the shear rate 
has none or minimal effects on their viscosity and shear stress (Figure 4.8). ST85 has 
the lowest apparent viscosity of 146.2 mPa s as compared to the other three 
microemulsions which have the apparent viscosity of around 200 mPa s at a shearing 
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rate of 50 s
-1
. This is due to the transition of the packing parameters of the surfactant, 
which favours the formation of water-in-oil microemulsions in ST85 as compared to the 
other surfactants (Mishra et al., 2000), thus ST85 has a lower viscosity. 
 
Figure 4.8: Rheological behaviour of microemulsions prepared with different types of Tween surfactants 
in a shear rate of 0.1 - 100 s
-1
. The symbols  = ST40,  = ST60,  = ST80, and  = ST85 
where opened symbols represent viscosity while solid symbols represent shear stress. 
 
The observation of TEM micrographs with 10,000 × and 20,000 × magnifications 
showed that microemulsion appeared to be rounded in shape and small in particle size 
as in Figure 4.9(a) and Figure 4.9(b) respectively. From the analysis, the averaged 
particle size of the sample, i.e. around 30 nm, is in agreement with the results obtained 
from the DLS. In spite of that, the micrographs of the TEM showed that the particles are 
polydispersed as there are a few particles which have a larger droplet size of nearly 60 
nm. This could be attributed to the fusion of oil droplet during the drying process or as a 
consequence of the droplet collapsing at a very low pressure of 10
-8
 mbar in the TEM 
chamber. Nevertheless, no particle flocculation was being observed in this system. 
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From the results attained, ST80 will be a more suitable candidate to encapsulate active 
ingredients as compared to other prepared microemulsions. This is because it has a 
better pH and viscosity than ST85 and smaller particle size than ST40 and ST60. That 
being so, active ingredients encapsulated ST80 was subjected to a further analysis for 
stability evaluation and in vitro release of active ingredients from ST80. 
 
 
(a) 
 
(b) 
Figure 4.9: TEM micrographs of ST80 microemulsion taken at different magnifications of (a) 10,000 × 
and (b) 20,000 × magnification. In this visualization, Carl Zeiss LIBRA
®
 120 is being 
employed. 
 
4.1.4 Characterization of κ-carrageenan-chitosan nanoparticle 
The κ-carrageenan-chitosan nanoparticle was synthesized by polyelectrolyte 
complexation using different ratio of 1% chitosan and 1% κ-carrageenan (v/v) to 
produce κ-carrageenan-chitosan nanoparticle. The polyelectrolyte complexation is 
achieved by electrostatic interaction between positively charged chitosan amino groups 
and negatively charged κ-carrageenan sulphate groups that present in the solution. The 
κ-carrageenan-chitosan nanoparticle was determined for its size, zeta potential and 
morphology in aqueous suspension whereas the yield, swelling percentage, and FTIR 
spectrum was being evaluated in the dried form. 
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The particle size analysis showed that the κ-carrageenan-chitosan nanoparticle 
synthesized is pH dependent as presented in Figure 4.10. Regardless of the pH during 
preparation, the κ-carrageenan-chitosan nanoparticle was shown to have the smallest 
average particle size around 400 nm when the mass ratio of κ-carrageenan:chitosan is in 
1:1. Additionally, when the amount of κ-carrageenan in the mixture was gradually 
increased, the particle size will decrease until it reached the equal mass ratio and 
subsequently followed by an increase in particle size.  
 
Figure 4.10: Particle size of κ-carrageenan-chitosan nanoparticle prepared at 30 ˚C using pre-dissolved 1% 
κ-carrageenan and 1% chitosan at different mass ratios in a pH ranged from 3 to 6. The 
symbols  = pH 3,  = pH 4,  = pH 5,  = pH 6. 
 
This phenomenon occurs as we presumed that κ-carrageenan and chitosan were in 1:1 
stoichiometry charge ratio. As a consequence, one sulphate group from the κ-
carrageenan will be ionically complexed with amino group from the chitosan (Figure 
4.11).  
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Figure 4.11: Schematic diagram of polyelectrolyte complexation for κ-carrageenan and chitosan. The 
positively charged amino group (red) of chitosan will react with negatively charged 
sulphate group (blue) of κ-carrageenan. 
 
When the amount of κ-carrageenan in the formulation was gradually increased with a 
decreased in the amount of chitosan, κ-carrageenan could further react with positively 
charged chitosan, to form a more compact structure with smaller particle size. Further 
increase in the amount of κ-carrageenan after the maximum complexation with chitosan 
was achieved, would reverse the scenario due to the presence of excess anionic charges 
in the solution. The negative charge will neutralize the positive charge of the chitosan, 
thus opposite charged interaction will eliminate the electrostatic repulsion and lead to 
precipitation of the κ-carrageenan-chitosan nanoparticle (Long et al., 2015). This was 
supported by the zeta potential measurement of the κ-carrageenan-chitosan nanoparticle, 
whereby an increase in κ-carrageenan in the solution would cause a decrease in the net 
zeta potential of the formulation (Figure 4.12). 
 
As a consequence, in the mixture where κ-carrageenan is in highly excess, the net 
charge becomes negative, indicates that κ-carrageenan dominate in the solution 
(Rodrigues et al., 2012). Apart from the properties of materials, the changes in pH 
would also affect the zeta potential of the prepared κ-carrageenan-chitosan nanoparticle. 
When the pH was being increased from pH 3 to pH 6, there is a drop in the zeta 
potential to a more negative magnitude. This is attributed by the present of more 
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alkalinity in the solution when the pH is increasing from pH 3 to pH 6, the particles tend 
to acquire more negative charge.  
 
Figure 4.12: Zeta potential of κ-carrageenan-chitosan nanoparticle prepared at 30 ˚C using pre-dissolved 
1% κ-carrageenan and 1% chitosan at different mass ratios in a pH ranged from 3 to 6. The 
symbols  = pH 3,  = pH 4,  = pH 5,  = pH 6. 
 
After the particle size and zeta potential evaluation, the κ-carrageenan-chitosan 
nanoparticle prepared was centrifuged and dried under vacuum oven to produce thin 
film for the evaluation of percentage yield, swelling percentage and FTIR analysis.  
 
The percentage yield of the κ-carrageenan-chitosan nanoparticle was highly depending 
on the mass ratio of κ-carrageenan:chitosan present in the solution (Table 4.4). Changes 
in pH do significantly affect the percentage yield for those dissolved in pH 3 to pH 5. 
Nevertheless, pH 6 showed a large magnitude of yield’s increment, which is attributed 
to the precipitation of undissolved chitosan in the solution during centrifugation. 
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Table 4.4: Percentage yield of dried κ-carrageenan-chitosan nanoparticle prepared at different pH 
κ-carrageenan:chitosan 
Yield of dried κ-carrageenan-chitosan nanoparticle (%) 
pH 3 pH 4 pH 5 pH 6 
1:5 8.61 ± 1.0 8.23 ± 0.8 8.08 ± 0.7 37.67 ± 0.8 
2:4 21.68 ± 1.1 20.22 ± 1.4 21.02 ± 2.0 45.02 ± 1.4 
3:3 33.30 ± 1.7 35.30 ± 1.3 37.30 ± 2.0 65.34 ± 1.3 
4:2 70.59 ± 1.9 78.23 ± 1.0 80.23 ± 1.6 82.63 ± 1.0 
5:1 49.67 ± 1.4 53.95 ± 1.6 55.95 ± 1.8 54.65 ± 2.0 
 
In the range of pH from 3 to 5 compared to pH 6, the percentage yield of the κ-
carrageenan-chitosan nanoparticle was increased by nearly two folds whenever the ratio 
of κ-carrageenan:chitosan was varied from 1:5 to 4:2. Further increase of κ-carrageenan 
causes the decrease in the percentage yield of κ-carrageenan-chitosan nanoparticle. The 
plausible explanation of this is that when the mass ratio of the κ-carrageenan was 
gradually increased, there were more κ-carrageenan which can complex with the 
chitosan presents in the solution until it reaches the maximum complexation at the ratio 
of 4:2. Nevertheless, when the ratio was further varied to 5:1, κ-carrageenan dominates 
the solution. The yield was decreased by the fact that there were not enough of chitosan 
which can complex with the κ-carrageenan present (Grenha et al., 2010). 
 
On the other hand, when the dried κ-carrageenan-chitosan nanoparticle was swelled in 
pH 7.4 phosphate buffer solution, it was observed that the swelling of the κ-
carrageenan-chitosan nanoparticle is pH dependent (Table 4.5). κ-carrageenan-chitosan 
nanoparticle swelled nearly 120% to 200%, depending on the mass ratio of κ-
carrageenan:chitosan. The κ-carrageenan-chitosan nanoparticle has a higher magnitude 
of swelling when it was initially prepared at a lower pH. This is attributed by the huge 
different in pH of the prepared κ-carrageenan-chitosan nanoparticle and phosphate 
buffer. This will further dissociate the interaction of amino group and sulphate group, 
which leads to greater swelling at a lower pH (Carneiro et al., 2013; Mahdavinia et al., 
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2015). Other than that, κ-carrageenan which has greater swelling ability than chitosan in 
aqueous, gives rise to the highest swelling percentage at κ-carrageenan:chitosan mass 
ratio of 5:1.  
 
Table 4.5:  Swelling percentage of dried κ-carrageenan-chitosan nanoparticle in pH 7.4 phosphate buffer 
solution 
κ-carrageenan:chitosan 
Swelling percentage (%) 
pH 3 pH 4 pH 5 pH 6 
1:5 163.63 ± 7.4 151.80 ± 3.6 140.08 ± 8.2 122.12 ± 2.4 
2:4 170.34 ± 4.3 149.65 ± 4.4 141.02 ± 9.4 127.40 ± 4.7 
3:3 174.32 ± 3.2 152.34 ± 3.6 144.30 ± 6.5 126.53 ± 3.1 
4:2 183.65 ± 5.7 165.56 ± 8.9 157.23 ± 6.5 137.81 ± 8.1 
5:1 191.12 ± 5.4 200.49 ± 5.9 195.69 ± 5.2 190.65 ± 4.9 
 
The FTIR analysis is used to identify the presence or absence of functional group in a 
sample when two or more substances are being complexed or dissociated. In order to 
present the complexation of κ-carrageenan-chitosan nanoparticle, FTIR spectra was 
scanned within the wavelength of 4000-450 cm
-1
 for κ-carrageenan, chitosan, mixture of 
κ-carrageenan with chitosan powder and dried κ-carrageenan-chitosan nanoparticle 
were displayed as in Figure 4.13. 
 
The FTIR spectrum of chitosan powder as in Figure 4.13(a) showed three typical peaks 
at 1650 cm
-1
, 1593 cm
-1
 and 1062 cm
-1
, which indicate the presence of amide I, amide II 
and glycosidic bond respectively. Amide I band is due to C=O stretching and vibration 
while amide II is due to the stretching vibration in combination with N-H bending. On 
the other hand, the FTIR spectrum of κ-carrageenan powder as in Figure 4.13(b) with 
four important peaks at 1229 cm
-1
, 1064 cm
-1
, 921 cm
-1
 and 845 cm
-1
, respectively 
indicate sulphate group, glycosidic bond, 3,6-anhydrogalactose and galactose-4-sulfate. 
In order to prove that both chitosan and κ-carrageenan were required to be in ionized 
solution form for complexation, the chitosan powder and κ-carrageenan powder were 
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mixed together at 1:1 mass ratio to identify the FTIR spectrum as in Figure 4.13(c). As 
a result, the FTIR spectrum showed a similar pattern with κ-carrageenan, indicating no 
complexation occurs. A new absorption band at 1548 cm
-1
 indicating the presence of 
NH3
+ 
 group and slight shift of the spectrum as in Figure 4.13(d), showed a possible 
formation of nanoparticle as a result of protonation and hydrogen bonding (Grenha et 
al., 2010; Li et al., 2013). 
 
Figure 4.13:  FTIR spectrum of (a) chitosan powder, (b) κ-carrageenan powder, (c) mixture of 1:1 κ-
carrageenan with chitosan powder and (d) κ-carrageenan-chitosan nanoparticle at a 
wavelength of 4000-450 cm
-1
. 
 
As a supplement, the morphology of the prepared κ-carrageenan-chitosan nanoparticle 
with 30,000 × and 120,000 × magnifications were shown to have a solid and compact 
structure which is rounded to irregular in shape as in Figure 4.14 (a) and Figure 4.14(b) 
respectively. The particle size of the sample was shown to be very much smaller than 
the DLS measurements as a result of an average value was obtained based on the 
intensity of particle. Large particles give higher intensity even though they have the 
same amount of particles as the small particles. In DLS measurement, when the 
measurement was as the number of particles calculated, the distribution of κ-
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carrageenan-chitosan nanoparticle majorly falls below 100 nm. This corresponds to the 
result of TEM and where the size of particle is less than 50 nm. 
 
  
(a) (b) 
Figure 4.14:  Morphology of κ-carrageenan-chitosan nanoparticle prepared at 1:1 mass ratio of κ-
carrageenan and chitosan. The micrographs were taken at (a) 30,000 × and (b) 120,000 × 
magnification by using JOEL JEM-2100F. 
 
The physical evaluation revealed that κ-carrageenan-chitosan nanoparticle was 
successfully produced by having a new absorption band at 1548 cm
-1
. Among the 
prepared combinations in pH 3 to 6, all κ-carrageenan and chitosan with a mass ratio of 
1:1 has the smallest particle size. Despite that, κ-carrageenan-chitosan nanoparticle 
prepared in pH 4 was being selected. This was because the κ-carrageenan-chitosan 
nanoparticle has a similar particle size of pH 5 of around 400 nm yet it has higher 
magnitude of zeta potential and better swelling percentage as compared to the one in pH 
5.  
 
4.2 Loading and encapsulation efficiency of active ingredients 
For each type of delivery carrier, formulation with the most desired physicochemical 
properties was selected for encapsulation or solubilisation of active ingredients. Both 
the loading efficiency and encapsulation efficiency of active ingredients with varied 
water solubility in delivery carrier were assessed. The changes in the physicochemical 
properties of active ingredients encapsulated delivery carrier were further discussed. 
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4.2.1 Encapsulated NLC 
The loading efficiency of active ingredients in NLC corresponds to the increment of the 
amount of active ingredient until it reaches the optimum loading amount (Figure 4.15). 
Lidocaine, which is slightly soluble in water has the highest loading efficiency in NLC 
as compared to caffeine and ascorbic acid which is sparingly soluble and very soluble in 
water respectively. The loading efficiency of lidocaine in NLC is at least four times 
higher than that of both ascorbic acid and caffeine. This is owing to the lipophilic 
properties of lidocaine, whereby it can easily incorporate into the lipid matrix of NLC 
than the other two active ingredients. 
 
Figure 4.15:  Active ingredients loaded NLC at different weight ratios of active ingredients to NLC. 
Where symbol  = ascorbic acid,  = caffeine, = lidocaine while AI = active ingredients, 
AI
e
 = loaded active ingredients. 
 
On the other hand, encapsulation efficiency of active ingredients showed that the 
encapsulation efficiency will increase gradually until it reaches its optimum 
encapsulation percentage, followed by a decrease in the encapsulation efficiency even 
though the loading efficiency is still increasing (Figure 4.16). Lidocaine, which is 
slightly soluble in water has the highest encapsulation efficiency of around 78% as 
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compared to caffeine of around 43%. Surprisingly, ascorbic acid which is very soluble 
in water, theoretically should have lower encapsulation efficiency than caffeine and 
lidocaine, anyhow gave a high encapsulation efficiency when the ratio of active 
ingredients to NLC is less than 0.05. This might be attributed to the adsorption of 
positively charged ascorbic acid on the surface of the NLC.  
 
Figure 4.16:  Encapsulation efficiency of active ingredients in varied weight ratios of active ingredients 
to NLC. Where symbol  = ascorbic acid,  = caffeine,  = lidocaine while W= weight, 
AI= active ingredients. 
 
The active ingredients encapsulated NLC were evaluated for their particle size and zeta 
potential. The encapsulation of caffeine and lidocaine in NLC, do not show any 
significant changes in their particle sizes. But, ascorbic acid encapsulated NLC showed 
a drastic change in particle size by two folds as compared to unencapsulated NLC 
(Figure 4.17). This is plausibly because the changes in the pH of the aqueous phase after 
addition of ascorbic acid induce aggregation to the NLC. Nevertheless, all samples 
showed only a slight increase in particle size over time. This indicates that despite there 
are changes in the particle size, the active ingredients encapsulated NLC still being 
remained as a stable formulation.  
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Figure 4.17:  Effect of active ingredients towards the stability of NLC with respect to storage time at 30 
˚C. Where symbols  = unloaded NLC,  = ascorbic acid,  = caffeine,  = lidocaine. 
 
The zeta potential of active ingredients encapsulated NLC corresponds to the value of 
unencapsulated active ingredients’ zeta potential in water. The zeta potential of ascorbic 
acid, caffeine and lidocaine were positively, zero and negatively charged respectively. 
This affects the overall charge of ascorbic acid, caffeine and lidocaine encapsulated 
NLC by showing an increase, no change and decrease in zeta potential correspondingly 
(Figure 4.18). Ascorbic acid, which is positively charged, neutralized some of the 
negatively charged NLC to give a more positive zeta potential. When the zeta potential 
was being evaluated for 4 weeks, it shows a slight increase in the zeta potential for all 
encapsulated or unencapsulated NLC. On top of that, the zeta potential becomes stable 
after Day 7
th
.  
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Figure 4.18:  Changes in zeta potential and stability of active ingredients loaded NLC as a function of 
storage time at 30 ˚C. Where symbols  = unloaded NLC,  = ascorbic acid,  = caffeine, 
 = lidocaine. 
 
4.2.2 Encapsulated liposome 
Both the loading efficiency and encapsulation efficiency of active ingredients in 
liposome from 0.1 to 0.5 mole ratio of active ingredients to fatty acid were tabulated in 
Table 4.6 and Table 4.7 respectively. When the mole ratio of active ingredients to fatty 
acid increased gradually from 0.1 to 0.5, the loading efficiency of active ingredients also 
increases for all active ingredients. The increment is owing to the presence of a higher 
concentration of active ingredients, hence increases the chance of active ingredients to 
be loaded in the liposome during the rehydration of fatty acid thin film. Apart from that, 
the loading and encapsulation efficiency of the liposomes are correlated with the 
solubility of the active ingredients in water. Lidocaine, which is slightly water soluble 
has the highest loading and encapsulation efficiency, followed by caffeine and ascorbic 
acid. Lidocaine, which is more lipid soluble has a high possibility to be embedded in the 
bilayer of the vesicle; caffeine, which can be soluble in both water and lipid can be 
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encapsulated either at the bilayer or the inner core of the vesicle while ascorbic acid, 
which is more water soluble is more likely to stay in the aqueous phase of liposome. 
 
Table 4.6:  Loading efficiency of oleic acid liposome prepared by using active ingredients with different 
water solubilities as a model to predict the capability of liposome in encapsulating active 
ingredients 
nAI/nFA Ascorbic Acid Caffeine Lidocaine 
0.1 2.18 ± 0.10 3.31 ± 0.36 8.82 ± 0.27 
0.2 3.96 ± 0.31 7.23 ± 0.19 17.07 ± 0.37 
0.3 5.73 ± 0.50 10.89 ± 0.28 24.85 ± 0.85 
0.4 7.71 ± 0.40 12.40 ± 0.36 32.67 ± 0.67 
0.5 9.49 ± 0.56 15.88 ± 0.30 38.97 ± 0.98 
nAI/nFA is equivalent to the mole ratio of active ingredients to oleic acid. Loading efficiency is the percentage calculated from the 
active ingredients loaded to a fixed amount of fatty acid. The loading efficiency increased when the active ingredients loaded 
increased. The active ingredient which is more hydrophobic tends to have a higher amount loaded in all the three fatty acid 
liposomes.  
 
Table 4.7:  Encapsulation efficiency of C18 unsaturated fatty acid liposome using three different active 
ingredients with varied water solubilities 
nAI/nFA Ascorbic Acid Caffeine Lidocaine 
0.1 21.79 ± 1.0 32.13 ± 3.5 88.57 ± 2.7 
0.2 19.79 ± 1.5 34.51 ± 0.9 84.51 ± 1.9 
0.3 19.11 ± 1.7 34.86 ± 0.9 83.17 ± 2.8 
0.4 19.29 ± 1.0 31.12 ± 0.9 80.87 ± 1.7 
0.5 18.98 ± 1.1 31.68 ± 0.6 78.29 ± 2.0 
nAI/nFA is equivalent to the mole ratio of active ingredients to oleic acid. Encapsulation efficiency is calculated from the amount 
encapsulated to initial amount loaded. The encapsulation efficiency mostly decreased when the active ingredients loaded increased. 
The active ingredient which is more hydrophobic tends to have a higher amount encapsulated in all the three fatty acid liposomes.  
 
On the contrary, the encapsulation efficiency showed a decrease with an increase of 
active ingredients to fatty acid mole ratio. When more active ingredients are being 
loaded, it has higher chances to be entrapped in liposomes. Yet, the amount loaded 
which does not increase proportionally, will reduce the encapsulation efficiency of the 
oleic acid liposome. Along with the encapsulation of active ingredients, changes in 
particle size (Figure 4.19) and zeta potential (Figure 4.20) was also evaluated.  
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Figure 4.19:  Particle size of oleic acid liposomes after loaded with different active ingredients at mole 
ratios of 0.1 to 0.5 active ingredients to fatty acid (nAI/nFA). Where symbol   = ascorbic 
acid,  = caffeine,  = lidocaine. 
 
When the active ingredients were loaded at mole ratios of 0.1 to 0.5 active ingredients 
to fatty acid, there were no apparent differences in the particle size and the zeta potential 
for both caffeine and lidocaine. Nevertheless, there was a slight difference in the 
particle size of ascorbic acid loaded liposome. This change was mainly caused by the 
acidic pH of ascorbic acid. The positive charge of ascorbic acid eased the formation of 
the liposome and thus produced a smaller particle size within the liposome formation 
range. Nevertheless, the situation was reversed when the amount of ascorbic acid added 
exceeded the buffering zone, which turned the liposome solution into an emulsion. As a 
result, the solution requires more sodium hydroxide to adjust the pH to 8.6, and the 
particle size gradually increased. The particle size of ascorbic acid loaded liposome 
corresponded to the loading efficiency, whereby those liposomes with a smaller particle 
size had a lower loading efficiency. 
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Figure 4.20:  Zeta potential of oleic acid liposomes after loaded with different active ingredients at 
mole ratios of 0.1 to 0.5 active ingredients to fatty acid (nAI/nFA). Where symbol  = 
ascorbic acid,  = caffeine,  = lidocaine. 
 
When the active ingredients loaded liposome was being monitored for 14 days, we 
noticed that the particle size of ascorbic acid loaded liposome increased drastically with 
the increase in active ingredient mole ratio whereas there is no effect on both the 
caffeine and lidocaine loaded liposomes (Table 4.8).  
 
Table 4.8:  Changes in particle size of active ingredients loaded oleic acid liposome after 2 weeks of 
storage at 30 ˚C 
nAI/nFA 
Particle Size (nm)  
Ascorbic acid Caffeine Lidocaine  
1
st
 14
th
 1
st
 14
th
 1
st
 14
th
  
0.1 68.86 103.3 104.9 93.05 107.5 107.3  
0.2 77.22 185.1 100.8 104.6 106.3 106.4  
0.3 101.6 211.8 98.42 102.3 112.8 109.5  
0.4 109.3 392.6 116.6 113.4 101.5 108.0  
0.5 107.4 446.0 115.6 114.3 107.2 109.0  
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The plausible reason is the presence of ascorbic acid in the solution which induces the 
aggregation of liposome. It is supported by the increase of zeta potential (Table 4.9) to a 
less negative value after Day 14
th
. This situation can be overcome by either coated the 
liposomes with polymer or lyophilized the solution once it is being prepared. 
 
Table 4.9:  Changes in zeta potential of active ingredients loaded oleic acid liposome after 2 weeks of 
storage at 30 ˚C 
nAI/nFA 
Zeta Potential (mV) 
Ascorbic acid Caffeine Lidocaine 
1
st
 14
th
 1
st
 14
th
 1
st
 14
th
 
0.1 -104 -101 -108 -104 -109 -106 
0.2 -107 -99.5 -105 -107 -104 -102 
0.3 -102 -98.6 -102 -102 -101 -105 
0.4 -105 -62 -103 -103 -101 -100 
0.5 -104 -52.3 -102 -106 -102 -101 
 
 
4.2.3 Encapsulated water-in-oil microemulsion  
The amount of active ingredients that could be loaded into the water-in-oil 
microemulsion depends on the solubility of active ingredients in water. On that account, 
the active ingredients were respectively dissolved in deionized water at the temperature 
of 30 ˚C with a gradual increment in the amount of 0.1 mg active ingredients. The 
optimum amount of which the active ingredients can be dissolved (Table 4.10) is 
determined when there is precipitation being observed at the bottom of the vials. 
 
Table 4.10: Optimum weight of active ingredients solubilized in 1 ml of deionized water 
 Approximate amount solubilized (mg ml
-1
) 
Ascorbic acid 345.6 
Caffeine 32.3 
Lidocaine 3.1 
 
The obtained amount of active ingredients being solubilized in deionized water is within 
the range when comparing with the water solubility as stated in drugbank (Law et al., 
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2014). Water solubility of lidocaine that obtained from drugbank is around 4.1 mg ml
-1
 
at 30 ˚C, which is close to our data of 3.1 mg ml-1. The variation in data might be due to 
the purity of the active ingredients when performing the experiments. Caffeine, on the 
other hand, has a water solubility of 21.6 mg ml
-1
 at 25 ˚C whereas ascorbic acid has a 
higher solubility of 400 mg ml
-1
 at 40 ˚C. In accordance to our data, the amount of 
active ingredients loaded in microemulsion, 3 mg ml
-1
 was selected based on the 
optimum concentration of lidocaine to standardize the amount of active ingredient 
solubilized in the aqueous phase of the prepared ST80 water-in-oil microemulsion. 
 
Ascorbic acid, caffeine and lidocaine with different water solubilities were individually 
loaded in ST80. The loading of the active ingredients showed no drastic change in the 
particle size, pH, conductivity and viscosity of ST80 as tabulated in Table 4.11. 
 
Table 4.11: Physical properties of active ingredients loaded ST80 microemulsions 
 pH 
Conductivity 
(mS cm
-1
) 
Apparent 
Viscosity (mPa s) 
Particle Size 
(nm) 
Blank ST80 7.36 ± 0.06 < 0.05 207.0 ± 0.9 22.42 ± 0.94 
Ascorbic Acid 7.08 ± 0.10 < 0.05 205.0 ± 0.5 22.84 ± 0.69 
Caffeine 7.31 ± 0.08 < 0.05 207.2 ± 0.8 22.98 ± 0.75 
Lidocaine 7.47 ± 0.07 < 0.05 205.6 ± 0.6 23.18 ± 0.82 
No apparent change in physical properties of ST80 microemulsion after loading of ascorbic acid, caffeine and lidocaine at 3 mg ml-1 
respectively. 
  
The size of the loaded microemulsion was similar to a blank microemulsion, whereby 
the particle size and apparent viscosity were around 23 nm and 206 mPa s, respectively. 
This is attributed to the non-ionic surfactant used in the preparation, whereby the 
additives had a negligible impact on the physical characteristic of microemulsion (Prieto 
& Calvo, 2013). However, there is a slight change in the pH of the ascorbic acid loaded 
microemulsion. The decrease in the pH of the microemulsion from 7.36 to 7.08 might 
be arised from the nature of ascorbic acid, which is acidic (pKa = 4.10). Nevertheless, a 
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slight change in the pH has no effect on the stability of the microemulsion, suggesting 
that ST80 is suitable for loading of a wide range of active ingredients. 
 
4.2.4 Encapsulated κ-carrageenan-chitosan nanoparticle 
The loading and encapsulation efficiency of active ingredients in κ-carrageenan-
chitosan nanoparticle, which affect by the hydrophilicity of active ingredients are shown 
in Figure 4.21 and Figure 4.22 respectively. 
 
Figure 4.21:  Mass ratio of active ingredients loaded into κ-carregeenan-chitosan nanoparticle. Where 
symbol  = ascorbic acid,  = caffeine,  = lidocaine while MAI/MCNP is the mass ratio of 
active ingredients to the weight of κ-carregeenan and chitosan and MAI
e
 is the mass of 
loaded active ingredients. 
 
It was shown that the loading of active ingredients in the κ-carrageenan-chitosan 
nanoparticle will gradually increases until it reaches their optimum loading efficiency. 
κ-carrageenan-chitosan nanoparticle was shown to have a low loading efficiency as it 
only could load a maximum mass of approximately 30% of the initial amount of the 
active ingredients. It was being hypothesized that the loading efficiency might follow 
the order of solubility or the protonated forms of the active ingredients in the solution. 
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From the result, it was shown that the loading of active ingredients depends on their 
solubility in water. Ascorbic acid, which is very soluble in water has the highest loading 
efficiency, followed by caffeine and lidocaine. Even though the protonated and 
unprotonated forms of the active ingredients in acidic condition might affect its 
solubility, the buffering effect of the continuous phase towards the active ingredients 
added nullified the condition. 
 
Figure 4.22:  Encapsulation efficiency of active ingredients in κ-carregeenan-chitosan nanoparticle. 
Where symbol  = ascorbic acid,  = caffeine,  = lidocaine while MAI/MCNP is the mass 
ratio of active ingredients to the weight of κ-carregeenan and chitosan. 
 
Ascorbic acid has the highest encapsulation efficiency of around 72% as compared to 
caffeine and lidocaine which shown to be around 28% and 17% respectively. The 
results shown are acceptable as lidocaine, which is less water soluble tends to recede 
from hydrophilic κ-carrageenan-chitosan nanoparticle. The encapsulation efficiency of 
caffeine and lidocaine was shown to increase gradually to its optimum percentage and 
then decrease even though the amount of active ingredients added is still increasing and 
do not exceed the optimum solubility. This pattern however, was not shown in ascorbic 
acid encapsulated κ-carrageenan-chitosan nanoparticle. This is plausibly due to the 
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repulsion of charge when more active ingredients were added to the solution, thus 
affects the encapsulation efficiency (Boonsongrit et al., 2006). 
 
Table 4.12:  Particle size and zeta potential of active ingredients loaded κ-carrageenan-chitosan 
nanoparticle 
MAI/MCNP 
 Particle Size (nm)  Zeta Potential (mV)  
 A B C  A B C  
0.1 
 382.9 
(5.8) 
399.0 
(1.3) 
389.5 
(3.3) 
 45.0 
(1.3) 
46.2 
(0.3) 
45.6 
(0.3) 
 
0.2 
 395.2 
(7.1) 
382.9 
(5.1) 
387.3 
(2.9) 
 45.8 
(0.8) 
46.5 
(1.5) 
44.8 
(0.9) 
 
0.3 
 384.4 
(7.2) 
387.6 
(2.4) 
390.1 
(2.5) 
 46.3 
(1.1) 
45.2 
(1.38) 
43.6 
(1.4) 
 
0.4 
 380.8 
(3.8) 
398.9 
(7.9) 
394.1 
(2.7) 
 45.4 
(0.2) 
47.1 
(0.8) 
42.9 
(1.15) 
 
0.5 
 392.6 
(5.3) 
413.5 
(3.6) 
395.6 
(4.4) 
 45.8 
(0.4) 
46.1 
(1.2) 
42.4 
(0.3) 
 
0.6 
 394.3 
(2.9) 
398.6 
(10.7) 
390.5 
(4.3) 
 46.1 
(0.8) 
45.6 
(0.5) 
42.6 
(0.3) 
 
0.7 
 395.7 
(5.5) 
391.1 
(2.6) 
409.2 
(0.43) 
 46.4 
(2.0) 
46.4 
(0.3) 
41.6 
(0.5) 
 
A is ascorbic acid encapsulated κ-carrageenan-chitosan nanoparticle, B is caffeine encapsulated κ-carrageenan-chitosan nanoparticle, 
C is lidocaine encapsulated κ-carrageenan-chitosan nanoparticle. The numbers in bracket indicate the standard deviation of the 
measurements taken. 
 
The changes in the particle size and zeta potential after loading of active ingredients in 
κ-carrageenan-chitosan nanoparticle were identified. The results indicate that there were 
no apparent change in the particle size of around 400 nm and zeta potential of 45 mV in 
the active ingredients loaded κ-carrageenan-chitosan nanoparticle when being prepared 
in 1:1 of κ-carrageenan to chitosan mass ratio at pH 4 as shown in Table 4.12. 
 
As a summary, active ingredients with different solubility in water can be encapsulated 
in all of the proposed delivery vehicles. Despite that, both NLC and liposome are more 
suitable for the encapsulation of active ingredients that are less water soluble whereas κ-
carrageenan-chitosan nanoparticle and microemulsion have preference over water 
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soluble active ingredients. The active ingredients’ release profile from those delivery 
vehicles are further discussed in the following section. 
 
4.3 Release profile of active ingredients from delivery vehicles 
The release profile of both unencapsulated active ingredients and enscapsulated active 
ingredients from different delivery vehicles were calculated and plotted as cumulative 
percentage release over time. Then, the plot were curve fitted into five types of kinetic 
models to determine the best model in order to explain the release profile of those 
delivery systems. 
 
4.3.1 Release profile of unencapsulated ingredients 
The release of unencapsulated active ingredients from the donor chamber to receptor 
chamber of Franz diffusion cell was in an ascending order of lidocaine < caffeine < 
ascorbic acid, as shown in Figure 4.23. 
 
Figure 4.23:  Release profile of unencapsulated active ingredients for 24 hours. Where symbol  = 
ascorbic acid,  = caffeine,  = lidocaine. 
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The release profile was expected for the reason that diffusion of active ingredients is 
hydrophilicity dependent. Ascorbic acid is highly soluble in water, followed by caffeine 
which is sparingly soluble in water and lidocaine which is slightly soluble in water. In 
the presence of one layer 5000 Da dialysis membrane separating the donor and receptor 
chambers, eases the diffusion of the active ingredients down the gradient concentration 
through the membrane. Therefore, the active ingredients which are more water soluble, 
have a higher possibility to diffuse into the receptor chamber than those which is more 
hydrophobic. 
 
This was followed by curve fitting of the unencapsulated active ingredients’ release 
profile into different kinetic models (Shoaib et al., 2006; Dash et al., 2010), to select the 
best model to describe the release pattern of the system. Their linear regression to the 
release curve and the rate constant were obtained by using DDSolver (Zhang et al., 
2010). The result for 24 hours curve fitting was tabulated in Table 4.13 and their plots 
was shown in Figure 4.24.  
 
Table 4.13:  Unencapsulated active ingredients’ rate constant and the linear regression of release curve 
after curve fit in different kinetic models for 24 hours 
 Ascorbic acid Caffeine Lidocaine 
Zero-order, k0 
(μg h-1) 
5.616 
R
2
= 0.234 
5.166 
R
2
= 0.662 
4.823 
R
2
= 0.759 
First-order, k1 
(h
-1
) 
0.219 
R
2
= 0.993 
0.139 
R
2
= 0.998 
0.111 
R
2
= 0.994 
Higuchi, kH 
(μg h-1/2) 
23.879 
R
2
= 0.894 
21.577 
R
2
= 0.972 
20.020 
R
2
= 0.987 
Hixson-Crowell, kHC 
(μg h-1) 
0.056 
R
2
= 0.972 
0.037 
R
2
= 0.987 
0.030 
R
2
= 0.981 
Korsmeyer-Peppas, kKP 
(h
-n
) 
33.028 
R
2
= 0.937 
22.062 
R
2
= 0.970 
18.452 
R
2
= 0.987 
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(a) Zero-order 
 
(b) First-order 
 
(c) Higuchi 
 
(d) Hixson-Crowell 
 
(e) Korsmeyer-Peppas 
Figure 4.24:  Curve fitting of unencapsulated active ingredients release profile in different kinetic models. 
Where symbol  = ascorbic acid,  = caffeine,  = lidocaine. The solid symbol represents 
the experimental plot while the opened symbol with line represents the predicted plot. 
 
Apart from that, the release curve was also fitted for the first 12 hours to evaluate the 
possible kinetic difference in the earlier part of release. The rate constant and their 
linear regression were shown in Table 4.14 whereas the plot was shown in Figure 4.25. 
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Table 4.14:  Unencapsulated active ingredients’ rate constant and the linear regression of release curve 
after curve fit in different kinetic models for the first 12 hours 
 Ascorbic acid Caffeine Lidocaine 
Zero-order, k0 
(μg h-1) 
9.223 
R
2
= 0.691 
7.671 
R
2
= 0.885 
6.768 
R
2
= 0.872 
First-order, k1 
(h
-1
) 
0.218 
R
2
= 0.988 
0.137 
R
2
= 0.996 
0.110 
R
2
= 0.985 
Higuchi, kH 
(μg h-1/2) 
27.482 
R
2
= 0.982 
22.448 
R
2
= 0.968 
19.847 
R
2
= 0.976 
Hixson-Crowell, kHC 
(μg h-1) 
0.058 
R
2
= 0.955 
0.038 
R
2
= 0.983 
0.032 
R
2
= 0.964 
Korsmeyer-Peppas, kKP 
(h
-n
) 
26.850 
R
2
= 0.982 
17.084 
R
2
= 0.994 
15.639 
R
2
= 0.997 
 
The curve fitting of release profile for the first 12 hours has shown a good linear 
regression towards first-order model in Figure 4.25(b) and Korsmeyer-Peppas model in 
Figure 4.25(e) as compared to zero-order model in Figure 4.25(a), Higuchi model in 
Figure 4.25(c) and Hixson-Crowell model in Figure 4.25(d). Between the two best fitted 
models, first-order model was still the more suitable selection to describe the release 
profile. In Korsmeyer-Peppas model, the mechanisms for release of active ingredients 
are in the order of solvent diffusion into the polymeric system, swelling of polymeric 
system, formation of gel, diffusion of active ingredients out of the polymeric system and 
dissolution of the polymeric system’s matrix. Henceforth, none of the steps described in 
Korsmeyer-Peppas model could fit into the scenario for the unencapsulated active 
ingredients. As a result, first order model which focus on the diffusion of active 
ingredients in one direction and concentration dependent, could best describe the release 
profile of unencapsulated active ingredients. 
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(a) Zero-order 
 
(b) First-order 
 
(c) Higuchi 
 
(d) Hixson-Crowell 
 
(e) Korsmeyer-Peppas 
Figure 4.25:  Curve fitting of unencapsulated active ingredients release profile for the first 12 hours in 
different kinetic models. Where symbol  = ascorbic acid,  = caffeine,  = lidocaine. The 
solid symbol represents the experimental plot while the opened symbol with line represents 
the predicted plot. 
 
4.3.2 Release profile of NLC 
The release profile of active ingredients from NLC showed a similar pattern as that of 
unencapsulated active ingredients, which are in the ascending order of release lidocaine 
< caffeine < ascorbic acid (Figure 4.26). Nevertheless, the rate of caffeine and lidocaine 
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released from encapsulated NLC were much lower than that of unencapsulated active 
ingredients while the rate of ascorbic acid was almost similar to the unencapsulated 
active ingredient. This suggested that, ascorbic acid which majorly adsorbs on the 
surface of NLC, would detach and permeate into the receptor chamber easier when there 
is a drop in the chemical potential than the other two active ingredients which are 
embedded in the matrix core of NLC. 
 
Figure 4.26:  Release profile of active ingredients from NLC for 24 hours. Where symbol  = ascorbic 
acid,  = caffeine, = lidocaine. 
 
The cumulative percentage release of active ingredients from NLC was then curve fitted 
into various kinetic models, to describe the release kinetic of the NLC. Their linear 
regression to the release curve and the rate constant were obtained by using DDSolver. 
The result for 24 hours curve fitting was tabulated in Table 4.15 and their curve fitting 
in zero-order model, first-order model, Higuchi model, Hixson-Crowell model and 
Korsmeyer-Peppas model were shown in Figure 4.27(a), Figure 4.27(b), Figure 4.27(c), 
Figure 4.27(d) and Figure 4.27(e) respectively.  
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Table 4.15:  Active ingredients’ rate constant and the linear regression of release curve from NLC after 
curve fit in different kinetic models for 24 hours 
 Ascorbic acid Caffeine Lidocaine 
Zero-order, k0 
(μg h-1) 
5.224 
R
2
= 0.454 
4.070 
R
2
= 0.870 
3.461 
R
2
= 0.927 
First-order, k1 
(h
-1
) 
0.160 
R
2
= 0.993 
0.075 
R
2
= 0.998 
0.055 
R
2
= 0.996 
Higuchi, kH 
(μg h-1/2) 
22.048 
R
2
= 0.939 
16.716 
R
2
= 0.963 
14.125 
R
2
= 0.964 
Hixson-Crowell, kHC 
(μg h-1) 
0.043 
R
2
= 0.966 
0.021 
R
2
= 0.985 
0.016 
R
2
= 0.988 
Korsmeyer-Peppas, kKP 
(h
-n
) 
26.963 
R
2
= 0.950 
11.981 
R
2
= 0.982 
8.767 
R
2
= 0.999 
 
Curve fitting of the cumulative release profile of active ingredients from NLC showed 
that the release kinetic fits well in all models except the zero-order model. The 
remaining four kinetic models which describe the kinetics have R
2
 values of at least 
0.939 for all active ingredients. Among the four models, first-order model has the best 
linear regression towards the original plots. Additionally, in the model, it was found that 
the rate constant of active ingredients’ release from NLC is at least 30% slower than the 
unencapsulated active ingredients. Hence, we hypothesized that at the initial phase of 
release, the active ingredients released were mostly from the continuous phase of the 
prepared NLC solution. This has caused a burst effect on the rate of active ingredients’ 
release, where most of the unencapsulated active ingredients could permeate into the 
receptor chamber. When the chemical potential gradient decreased, the encapsulated 
active ingredients from NLC will gradually partition into the continuous phase. At this 
stage, the release rate would be much lower as more energy was required to overcome 
the phase barrier for it to be release to the continuous phase. 
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(a) Zero-order 
 
(b) First-order 
 
(c) Higuchi 
 
(d) Hixson-Crowell 
 
(e) Korsmeyer-Peppas 
Figure 4.27:  Curve fitting of active ingredients’ release profile from NLC in different kinetic models for 
24 hours. Where symbol  = ascorbic acid,  = caffeine, = lidocaine. The solid symbol 
represents the experimental plot while the opened symbol with line represents the predicted 
plot. 
 
In order to show a more ‘real-time’ release kinetic, the release curve was fitted for the 
first 12 hours, to evaluate the possible kinetic difference in the initial part of release. 
The rate constant and their linear regression were tabulated in Table 4.16 whereas their 
curve fitting in zero-order model, first-order model, Higuchi model, Hixson-Crowell 
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model and Korsmeyer-Peppas model were shown in Figure 4.28(a), Figure 4.28(b), 
Figure 4.28(c), Figure 4.28(d) and Figure 4.28(e) respectively. 
 
Table 4.16:  Active ingredients’ rate constant and the linear regression of release curve from NLC after 
curve fit in different kinetic models for the first 12 hours 
 Ascorbic acid Caffeine Lidocaine 
Zero-order, k0 
(μg h-1) 
8.314 
R
2
= 0.818 
5.429 
R
2
= 0.978 
4.316 
R
2
= 0.947 
First-order, k1 
(h
-1
) 
0.165 
R
2
= 0.994 
0.076 
R
2
= 0.997 
0.056 
R
2
= 0.986 
Higuchi, kH 
(μg h-1/2) 
24.521 
R
2
= 0.981 
15.588 
R
2
= 0.917 
12.508 
R
2
= 0.947 
Hixson-Crowell, kHC 
(μg h-1) 
0.045 
R
2
= 0.971 
0.023 
R
2
= 0.997 
0.017 
R
2
= 0.977 
Korsmeyer-Peppas, kKP 
(h
-n
) 
20.942 
R
2
= 0.991 
8.406 
R
2
= 0.999 
8.091 
R
2
= 0.999 
 
The curve fitting of release profile for the first 12 hours has shown a good linear 
regression towards almost all of the kinetic models. Nevertheless, Korsmeyer-Peppas 
model was shown to have the nearest R
2
 values to the original plot followed by first-
order model. Since the release exponent of active ingredient is between the value of 
0.43 and 1.00 for Korsmeyer-Peppas model, this indicated non-Fickian transport for 
NLC system during the first 12 hours. This demonstrated the possibility that when the 
NLC solution came into contact with the release medium in receptor chamber, the active 
ingredients close to the surface of NLC was release by diffusion. At the later time, it is 
plausible that the NLC undergo some structural changes either by the effects of 
temperature or chemical potential gradient, causing the release to be continued in a 
linear manner (Nagaich and Gulati, 2016; Üner et al., 2014). However, the more 
suitable model to describe the release of active ingredients from NLC would be first-
order model whereby the linear regression is considered as the best in both 12 and 24 
hours. 
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(a) Zero-order 
 
(b) First-order 
 
(c) Higuchi 
 
(d) Hixson-Crowell 
 
(e) Korsmeyer-Peppas 
Figure 4.28:  Curve fitting of active ingredients’ release profile from NLC in different kinetic models for 
the first 12 hours. Where symbol  = ascorbic acid,  = caffeine, = lidocaine. The solid 
symbol represents the experimental plot while the opened symbol with line represents the 
predicted plot. 
 
4.3.3 Release profile of liposome 
The release profiles of active ingredients from oleic acid liposome are shown in an 
ascending order of lidocaine < caffeine < ascorbic acid (Figure 4.29). The release rate of 
ascorbic acid, caffeine and lidocaine from oleic acid liposome is 5%, 17% and 43% 
103 
 
slower than the unencapsulated active ingredients respectively. This is plausibly due to 
the encapsulation efficiency of those active ingredients in oleic acid liposome. The 
presence of unencapsulated active ingredients in the continuous phase, caused a burst 
effect which leads to high release rate at the initial phase of active ingredients release 
yet the overall release rate is slower than the free active ingredients due to encapsulation. 
 
Figure 4.29:  Release profile of active ingredients from liposome for 24 hours. Where symbol  = 
ascorbic acid,  = caffeine, = lidocaine. 
 
The cumulative percentage release of active ingredients from oleic acid liposome was 
then curve fitted into various kinetic models, to describe the release kinetic of the 
liposome. Their linear regression to the release curve and the rate constant were 
obtained by using DDSolver. The result for 24 hours curve fitting was tabulated in 
Table 4.17 and their curve fitting in zero-order model, first-order model, Higuchi model, 
Hixson-Crowell model and Korsmeyer-Peppas model were shown in Figure 4.30(a), 
Figure 4.30(b), Figure 4.30(c), Figure 4.30(d) and Figure 4.30(e) respectively.  
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Table 4.17:  Active ingredients’ rate constant and the linear regression of release curve from oleic acid 
liposome after curve fit in different kinetic models for 24 hours 
 Ascorbic acid Caffeine Lidocaine 
Zero-order, k0 
(μg h-1) 
5.658 
R
2
= 0.345 
4.751 
R
2
= 0.585 
3.813 
R
2
= 0.953 
First-order, k1 
(h
-1
) 
0.208 
R
2
= 0.992 
0.116 
R
2
= 0.979 
0.064 
R
2
= 0.996 
Higuchi, kH 
(μg h-1/2) 
23.970 
R
2
= 0.914 
19.924 
R
2
= 0.974 
15.477 
R
2
= 0.943 
Hixson-Crowell, kHC 
(μg h-1) 
0.054 
R
2
= 0.987 
0.031 
R
2
= 0.933 
0.018 
R
2
= 0.999 
Korsmeyer-Peppas, kKP 
(h
-n
) 
31.219 
R
2
= 0.938 
22.302 
R
2
= 0.976 
8.227 
R
2
= 0.996 
 
The release of active ingredients from oleic acid liposome has good linear regression 
towards all the kinetic models except for zero-order model. Among the kinetic models, 
first-order model has the closest R
2
 values of at least 0.979 regardless of the active 
ingredients.  In first-order model, the rate of active ingredient is a function of the 
amount of active ingredient remaining in the donor chamber. During the early stage of 
release, the rates of active ingredients’ diffusion were high. This was due to chemical 
potential gradient present in the liposomal solution was abundant due to unencapsulated 
active ingredients as compared to the amount in receptor chamber. When the 
concentration of active ingredient in the donor chamber started to deplete after certain 
time of diffusion, the rate of active ingredients being released from the continuous phase 
of liposome solution also became lower. At this point, the active ingredients 
encapsulated in either the aqueous core or lipid bilayer of liposome, will start to diffuse 
out slowly to the environment through osmosis. As a result, the rate of diffusion slowed 
down until it reached plateau, whereby all the active ingredients were diffused to the 
receptor part. Additionally, the release rate of active ingredients from liposome is 
slightly faster than NLC. This is possibly attributed by the particle size of liposome 
which is smaller than NLC, ease the energy barrier for active ingredients release from 
liposome as compared to NLC. 
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(a) Zero-order 
 
(b) First-order 
 
(c) Higuchi 
 
(d) Hixson-Crowell 
 
(e) Korsmeyer-Peppas 
Figure 4.30:  Curve fitting of active ingredients’ release profile from oleic acid liposome in different 
kinetic models for 24 hours. Where symbol  = ascorbic acid,  = caffeine, = lidocaine. 
The solid symbol represents the experimental plot while the opened symbol with line 
represents the predicted plot. 
 
Apart from that, the release curve was fitted for the first 12 hours of release, to evaluate 
the possible kinetic difference in the initial part of release. The rate constant and their 
linear regression were tabulated in Table 4.18 whereas the curve fit in zero-order model, 
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first-order model, Higuchi model, Hixson-Crowell model and Korsmeyer-Peppas model 
were shown in Figure 4.31(a), Figure 4.31(b), Figure 4.31(c), Figure 4.31(d) and Figure 
4.31(e) respectively. 
 
Table 4.18:  Active ingredients’ rate constant and the linear regression of release curve from oleic acid 
liposome after curve fit in different kinetic models for the first 12 hours 
 Ascorbic acid Caffeine Lidocaine 
Zero-order, k0 
(μg h-1) 
9.202 
R
2
= 0.798 
7.209 
R
2
= 0.817 
4.549 
R
2
= 0.979 
First-order, k1 
(h
-1
) 
0.204 
R
2
= 0.988 
0.125 
R
2
= 0.977 
0.060 
R
2
= 0.998 
Higuchi, kH 
(μg h-1/2) 
27.188 
R
2
= 0.989 
21.264 
R
2
= 0.985 
13.063 
R
2
= 0.918 
Hixson-Crowell, kHC 
(μg h-1) 
0.055 
R
2
= 0.976 
0.035 
R
2
= 0.947 
0.018 
R
2
= 0.995 
Korsmeyer-Peppas, kKP 
(h
-n
) 
24.034 
R
2
= 0.996 
18.277 
R
2
= 0.995 
7.078 
R
2
= 0.999 
 
The release profile for the first 12 hours has shown to be similar to 24 hours curve 
fitting, whereby the plots have good linear regression towards all of the kinetic models 
except zero-order model. Nevertheless, unlike 24 hours curve fitting, 12 hours curve 
fitting has the closest R
2
 value towards Korsmeyer-Peppas model instead of first-order 
model. This suggested that the release of active ingredients from liposome is in biphasic, 
whereby the active ingredients in the continuous phase will diffuse into the receptor 
chamber in a faster rate due to burst release. When the amount of active ingredient in 
donor chamber gradually depleted, chemical potential difference between donor and 
receptor chamber also decreased. This has led to a change in release rate to be more 
linear. Additionally, the active ingredients’ release exponent which falls between the 
value of 0.43 and 1.00 for Korsmeyer-Peppas model, indicated non-Fickian transport 
for oleic acid liposome during the first 12 hours. In spite of that, the more suitable 
model to describe the release of active ingredients from liposome would be first-order 
model whereby the linear regression is more similar for 12 and 24 hours. 
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(a) Zero-order 
 
(b) First-order 
 
(c) Higuchi 
 
(d) Hixson-Crowell 
 
(e) Korsmeyer-Peppas 
Figure 4.31:  Curve fitting of active ingredients’ release profile from liposome in different kinetic models 
for the first 12 hours. Where symbol  = ascorbic acid,  = caffeine, = lidocaine. The 
solid symbol represents the experimental plot while the opened symbol with line represents 
the predicted plot. 
 
4.3.4 Release profile of water-in-oil microemulsion 
The release profile of active ingredients from microemulsion can evidently represent the 
ability of the active ingredients to be soluble in the oil phase. The cumulative 
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percentage release of active ingredient is in an ascending order of ascorbic acid < 
caffeine < lidocaine (Figure 4.32). 
 
Figure 4.32:  Release profile of active ingredients from water-in-oil microemulsion for 24 hours. Where 
symbol  = ascorbic acid,  = caffeine, = lidocaine. 
 
ST80 microemulsion exhibits slow release behavior as the cumulative percentage 
release of active ingredients reached at most 64 % after 24 hours. The release of active 
ingredients from water-in-oil microemulsion depends on the partition coefficient of the 
active ingredients to the oil phase. Lidocaine, which is more hydrophobic than caffeine 
and ascorbic acid, solubilized freely in oil. Hence, lidocaine can be partition easily into 
the oil phase for release compared to caffeine and ascorbic acid. As a consequence, the 
release of lidocaine from ST80 was shown to be two folds and four folds faster than 
caffeine and ascorbic acid.   
 
In addition, the release profile was fitted into various kinetic models to describe the 
possible mechanism of active ingredients’ release from ST80. Their linear regression to 
the release curve and the rate constant were obtained by using DDSolver. The result for 
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24 hours curve fitting was tabulated in Table 4.19 and their curve fitting in zero-order 
model, first-order model, Higuchi model, Hixson-Crowell model and Korsmeyer-
Peppas model were shown in Figure 4.33(a), Figure 4.33(b), Figure 4.33(c), Figure 
4.33(d) and Figure 4.33(e) respectively.  
 
Table 4.19:  Active ingredients’ rate constant and the linear regression of release curve from 
microemulsion after curve fit in different kinetic models for 24 hours 
 Ascorbic acid Caffeine Lidocaine 
Zero-order, k0 
(μg h-1) 
0.630 
R
2
= 0.701 
1.424 
R
2
= 0.901 
2.928 
R
2
= 0.939 
First-order, k1 
(h
-1
) 
0.007 
R
2
= 0.739 
0.017 
R
2
= 0.943 
0.042 
R
2
= 0.992 
Higuchi, kH 
(μg h-1/2) 
2.623 
R
2
= 0.995 
5.834 
R
2
= 0.976 
11.929 
R
2
= 0.960 
Hixson-Crowell, kHC 
(μg h-1) 
0.002 
R
2
= 0.727 
0.005 
R
2
= 0.931 
0.013 
R
2
= 0.983 
Korsmeyer-Peppas, kKP 
(h
-n
) 
2.656 
R
2
= 0.995 
4.035 
R
2
= 0.999 
7.045 
R
2
= 0.999 
 
Among all of the kinetic models, release of active ingredients from water-in-oil 
microemulsion has the closest linear regression to both the Higuchi and Korsmeyer-
Peppas models. In Higuchi model, it is being presumed that the initial drug 
concentration in the matrix is much higher than drug solubility; drug diffusion takes 
place only in one dimension; drug particles are much smaller than system thickness; 
matrix swelling and dissolution are negligible; drug diffusivity is constant and perfect 
sink conditions are always attained in the release environment. Whereas, in Korsmeyer-
Peppas model, the mechanisms for release of active ingredients are in the order of 
solvent diffusion into the polymeric system, swelling of polymeric system, formation of 
gel, diffusion of active ingredients out of the polymeric system and dissolution of the 
polymeric system’s matrix. Between the two models, Higuchi model would be a more 
appropriate model to describe the release of active ingredients from ST80 because 
swelling and dissolution of ST80 is negligible in this system.   
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(a) Zero-order 
 
(b) First-order 
 
(c) Higuchi 
 
(d) Hixson-Crowell 
 
(e) Korsmeyer-Peppas 
Figure 4.33:  Curve fitting of active ingredients’ release profile from water-in-oil microemulsion in 
different kinetic models for 24 hours. Where symbol  = ascorbic acid,  = caffeine, = 
lidocaine. The solid symbol represents the experimental plot while the opened symbol with 
line represents the predicted plot. 
 
In order to further evaluate the mechanism, the first 12 hours of release profile was 
curve fitted into various kinetic models. The rate constant and their linear regression 
was tabulated in Table 4.20 whereas their curve fitting plot in zero-order model, first-
order model, Higuchi model, Hixson-Crowell model and Korsmeyer-Peppas model 
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were shown in Figure 4.34(a), Figure 4.34(b), Figure 4.34(c), Figure 4.34(d) and Figure 
4.34(e) respectively. 
 
Table 4.20:  Active ingredients’ rate constant and the linear regression of release curve from 
microemulsion after curve fit in different kinetic models for first 12 hours 
 Ascorbic acid Caffeine Lidocaine 
Zero-order, k0 
(μg h-1) 
0.902 
R
2
= 0.773 
1.824 
R
2
= 0.905 
3.591 
R
2
= 0.934 
First-order, k1 
(h
-1
) 
0.009 
R
2
= 0.795 
0.020 
R
2
= 0.932 
0.044 
R
2
= 0.974 
Higuchi, kH 
(μg h-1/2) 
2.671 
R
2
= 0.990 
5.326 
R
2
= 0.968 
10.431 
R
2
= 0.955 
Hixson-Crowell, kHC 
(μg h-1) 
0.003 
R
2
= 0.788 
0.007 
R
2
= 0.923 
0.014 
R
2
= 0.963 
Korsmeyer-Peppas, kKP 
(h
-n
) 
2.434 
R
2
= 0.994 
3.924 
R
2
= 0.999 
7.062 
R
2
= 0.999 
 
Similar to curve fitting of 24 hours, the first 12 hours of active ingredients release from 
ST80 falls into either Higuchi model or Korsmeyer-Peppas model. Even though the 
active ingredients’ release profile has a closer linear regression to Korsmeyer-Peppas 
model, Higuchi model is the more suitable model to describe the release of active 
ingredients from ST80. The pathway taken is first the partition of the active ingredients 
from aqueous disperse phase into oil continuous phase. This depends on the partition 
coefficient of the active ingredients into olive oil.  Lidocaine which is the most soluble 
active ingredients in olive oil, ease the partition of lidocaine into the oil phase compared 
to the other two active ingredients. The active ingredients which gradually increased 
their concentration in continuous phase through partition, creates a chemical potential in 
the donor chamber. This chemical potential gradient enabled the active ingredients to be 
diffused through the separation membrane into the receptor chamber. 
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(a) Zero-order 
 
(b) First-order 
 
(c) Higuchi 
 
(d) Hixson-Crowell 
 
(e) Korsmeyer-Peppas 
Figure 4.34:  Curve fitting of active ingredients’ release profile from microemulsion in different kinetic 
models for the first 12 hours. Where symbol  = ascorbic acid,  = caffeine, = lidocaine. 
The solid symbol represents the experimental plot while the opened symbol with line 
represents the predicted plot. 
 
4.3.5 Release profile of κ-carrageenan-chitosan nanoparticle 
The cumulative percentage release of active ingredients from the κ-carrageenan-
chitosan nanoparticle was shown to be very low (Figure 4.35) as compared to the other 
three systems being described previously. The release profile of active ingredients from 
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κ-carrageenan-chitosan nanoparticle is in the ascending order of ascorbic acid < caffeine 
< lidocaine. It was unexpected that the ascorbic acid and caffeine which is freely soluble 
in water and sparingly soluble in water respectively, had a lower release rate than 
lidocaine which is slightly soluble in water. This might deduce that ascorbic acid, which 
was ionized at pH 7.4 would take a longer time to overcome the ionic forces before it 
could be released to the continuous phase. Lidocaine, which is more hydrophobic could 
repulse more easily to the continuous phase, thereby a higher amount of release could 
be attained (Boonsongrit et al., 2006). Sudden increased in release of lidocaine after 14 
hours could be attributed to the compactness of dried κ-carrageenan-chitosan 
nanoparticle, where more energy is required to overcome the barrier for release. 
 
Figure 4.35:  Release profile of active ingredients from κ-carrageenan-chitosan nanoparticle for 24 hours. 
Where symbol  = ascorbic acid,  = caffeine, = lidocaine. 
 
The κ-carrageenan-chitosan nanoparticle, which has a low cumulative percentage 
release of active ingredients were fitted into different kinetic models. Their linear 
regression to the release curve and the rate constant were obtained by using DDSolver. 
The result for 24 hours curve fitting was tabulated in Table 4.21 and their curve fitting 
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in zero-order model, first-order model, Higuchi model, Hixson-Crowell model and 
Korsmeyer-Peppas model were shown in Figure 4.36(a), Figure 4.36(b), Figure 4.36(c), 
Figure 4.36(d) and Figure 4.36(e) respectively. 
 
Table 4.21:  Active ingredients’ rate constant and the linear regression of release curve from κ-
carrageenan-chitosan nanoparticle after curve fit in different kinetic models for 24 hours 
 Ascorbic acid Caffeine Lidocaine 
Zero-order, k0 
(μg h-1) 
0.050 
R
2
= 0.989 
0.122 
R
2
= 0.811 
0.367 
R
2
= 0.860 
First-order, k1 
(h
-1
) 
0.001 
R
2
= 0.990 
0.001 
R
2
= 0.815 
0.004 
R
2
= 0.853 
Higuchi, kH 
(μg h-1/2) 
0.199 
R
2
= 0.832 
0.501 
R
2
= 0.961 
1.443 
R
2
= 0.684 
Hixson-Crowell, kHC 
(μg h-1) 
0.000 
R
2
= 0.990 
0.000 
R
2
= 0.813 
0.001 
R
2
= 0.855 
Korsmeyer-Peppas, kKP 
(h
-n
) 
0.041 
R
2
= 0.991 
0.421 
R
2
= 0.965 
0.078 
R
2
= 0.890 
 
 It was found that Korsmeyer-Peppas model was the best to describe the release profile 
of κ-carrageenan-chitosan nanoparticle. The curve fitting into Korsmeyer-Peppas model 
was anticipated as the model was usually applied on polymeric system. In Korsmeyer-
Peppas model, the mechanisms for release of active ingredients are in the steps of 
solvent diffusion into the polymeric system, swelling of polymeric system, formation of 
gel, diffusion of active ingredients out of the polymeric system and dissolution of the 
polymeric system’s matrix. It was believed that active ingredients encapsulated in κ-
carrageenan-chitosan nanoparticle was being released by repulsion and diffusion 
because there was no significant loss in mass of the κ-carrageenan-chitosan nanoparticle 
after a long period swelling in the pH 7.4 phosphate buffer solution. 
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(a) Zero-order 
 
(b) First-order 
 
(c) Higuchi 
 
(d) Hixson-Crowell 
 
(e) Korsmeyer-Peppas 
Figure 4.36:  Curve fitting of active ingredients’ release profile from κ-carrageenan-chitosan nanoparticle 
in different kinetic models for 24 hours.  Where symbol  = ascorbic acid,  = caffeine, = 
lidocaine. The solid symbol represents the experimental plot while the opened symbol with 
line represents the predicted plot. 
 
Despite that the Korsmeyer-Peppas model was shown to have the closest linear 
regression to the original plot of active ingredient release, the R
2
 value was still far from 
expectation. For that reason, the first 12 hours of active ingredients release profile was 
curve fitted into various kinetic models to further evaluate the possible mechanism. The 
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rate constant and their linear regression were tabulated in Table 4.22 whereas curve 
fitting of plot in zero-order model, first-order model, Higuchi model, Hixson-Crowell 
model and Korsmeyer-Peppas model were shown in Figure 4.37(a), Figure 4.37(b), 
Figure 4.37(c), Figure 4.37(d) and Figure 4.37(e) respectively. 
 
Table 4.22:  Active ingredients’ rate of release from κ-carrageenan-chitosan nanoparticle after curve 
fitting in different kinetic models for the first 12 hours  
 Ascorbic acid Caffeine Lidocaine 
Zero-order, k0 
(μg h-1) 
0.051 
R
2
= 0.988 
0.159 
R
2
= 0.528 
0.318 
R
2
= 0.379 
First-order, k1 
(h
-1
) 
0.001 
R
2
= 0.988 
0.002 
R
2
= 0.533 
0.003 
R
2
= 0.392 
Higuchi, kH 
(μg h-1/2) 
0.141 
R
2
= 0.798 
0.476 
R
2
= 0.992 
0.962 
R
2
= 0.944 
Hixson-Crowell, kHC 
(μg h-1) 
0.000 
R
2
= 0.988 
0.001 
R
2
= 0.532 
0.001 
R
2
= 0.388 
Korsmeyer-Peppas, kKP 
(h
-n
) 
0.034 
R
2
= 0.997 
0.528 
R
2
= 0.999 
1.132 
R
2
= 0.966 
 
From the result, it can be clearly seen that Korsmeyer-Peppas model is the best to 
describe the release of active ingredients from κ-carrageenan-chitosan nanoparticle for 
the first 12 hours. Regardless to the type of active ingredients, the R
2
 values were the 
closest to the active ingredients cumulative plots with the minimum value of 0.966. The 
n value for ascorbic acid release which was higher than 1.00 indicated super case II 
transport. The other two active ingredients, caffeine and lidocaine had n values which 
were lesser than 0.50 indicated Fickian diffusion. For super case II transport, it 
suggested that the release of active ingredients from κ-carrageenan-chitosan 
nanoparticle involved swelling and relaxation of the polymer whereas for Fickian 
diffusion, the mechanisms involved polymer relaxation followed by diffusion of active 
ingredients (Sahoo et al., 2012). 
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(a) Zero-order 
 
(b) First-order 
 
(c) Higuchi 
 
(d) Hixson-Crowell 
 
(e) Korsmeyer-Peppas 
Figure 4.37:  Curve fitting of active ingredients’ release profile from κ-carrageenan-chitosan nanoparticle 
in different kinetic models for the first 12 hours. Where symbol  = ascorbic acid,  = 
caffeine, = lidocaine. The solid symbol represents the experimental plot while the opened 
symbol with line represents the predicted plot. 
 
 
118 
 
CHAPTER 5: CONCLUSION 
5.1 Summary 
As a summary, each of the system has been characterized to select the best formulation 
for the encapsulation and release of active ingredients with varied solubility in water, 
namely ascorbic acid which is soluble in water, caffeine which is sparingly soluble in 
water and lidocaine which is slightly soluble in water. A short summary on each 
systems were described. 
 
NLC is a lipid nanoparticle dispersed in aqueous continuous phase. Among the five 
NLC formulations prepared by using fatty acid mixture and Span 40, NLC 3 showed to 
be the most suitable formulation. NLC 3 exhibit high stability in continuous particle 
size and zeta potential measurements, good thermal profile in DSC evaluation, and with 
acceptable morphology when visualized under TEM. NLC is efficient in encapsulating 
lidocaine followed by caffeine and ascorbic acid. Nevertheless, the zeta potential of the 
active ingredients will affect the physical properties of the NLC. As a result, this will 
caused adsorption of active ingredients on the NLC and further induced aggregation of 
the NLC. The release of active ingredients from NLC was slower than the 
unencapsulated active ingredients, indicated the possibility of NLC as a slow release 
delivery carrier. In addition, the release has a good linear regression towards first-order 
model suggest that the release is concentration dependent.   
 
Fatty acid liposome is a lipid bilayer with an aqueous core suspend in aqueous 
continuous phase. It is a pH sensitive liposome whereby it changes its phases according 
to the changes of pH. Among the three fatty acid liposomes, the oleic acid liposome 
displayed the best physical properties as it had the lowest critical vesicle concentration 
of 0.09 mM, a stable particle size of approximately 100 nm, and the highest loading 
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capacity compared to linoleic acid and linolenic acid liposomes. The loading 
efficiencies of the active ingredients in the liposomes were correlated to the degree of 
unsaturation of the fatty acids, whereby those with more unsaturated double bonds had 
lower encapsulation efficiencies. Liposome is expedient in encapsulating different types 
of active ingredients, particularly those with high hydrophobicity. The release profile of 
active ingredients from the oleic acid liposome which is slightly slower than 
unencapsulated active ingredients suggested that the release could be fast burst from the 
continuous phase followed by slow release when the concentration was depleted. 
Additionally, this release kinetic follows first-order release which is depends on 
chemical potential gradient. 
 
A stable water-in-oil microemulsion has been successfully prepared by a mild agitation 
of olive oil, water and non-ionic mixed surfactant. Among the microemulsions prepared, 
ST80 is more suitable for topical application as it has a better pH and higher viscosity as 
compared to ST85, and it is smaller in size as compared to ST40 and ST60 due to its 
critical packing parameters of surfactants. ST80 is also suitable as a model for the 
loading of many types of active ingredients. Results obtained from the active 
ingredients’ release study show that the release profile is hydrophobicity dependent. 
Lidocaine, which is more hydrophobic, has a higher release rate from the 
microemulsion to the receptor chamber as compared to slightly soluble in water caffeine 
and very soluble in water ascorbic acid. The slow constant release rate of the active 
ingredients suggests sustained release properties of the ST80 microemulsion. In addition, 
the best kinetic model to describe the release would be Higuchi model. 
 
Based on the new absorption band at 1584 cm
-1
 and TEM micrographs, κ-carrageenan-
chitosan nanoparticle was shown to be successfully synthesized. The particle size, zeta 
120 
 
potential, yield percentage and swelling percentage are highly affected by the 
composition of polymers and the pH of solution. The encapsulation efficiency of κ-
carrageenan-chitosan nanoparticle exhibited higher preference towards more water 
soluble active ingredients. Nevertheless, the release profile exhibit a reverse pattern 
whereby those which is less water soluble could release at faster rate. This is attributed 
by ionic interaction between the active ingredients and polymer whereby it could 
strongly retain in the κ-carrageenan-chitosan nanoparticle. The release profile suggested 
that κ-carrageenan-chitosan nanoparticle is suitable for prolonged release. The release 
kinetic follows Korsmeyer-Peppas model indicated that the release involved the 
swelling and relaxation of the polymers. 
 
The properties of each delivery vehicles were summarized as in Table 5.1. 
 
Table 5.1: The properties of each active ingredient’s delivery vehicles 
 NLC Liposome 
Water-in-oil 
microemulsion 
κ-carrageenan-
chitosan 
nanoparticle 
Schematic 
diagram 
    
     
Disperse 
phase 
 
Oil 
 
Oil 
 
Aqueous 
 
Polymer in aqueous 
 
Continuous 
phase 
 
Aqueous 
 
Aqueous 
 
Oil 
 
Aqueous 
 
Average 
particle size 
~250 nm ~100 nm ~30 nm ~400 nm 
     
Morphology 
Rounded to 
elongated 
Rounded Rounded 
Rounded to 
irregular 
     
Encapsulatio
n efficiency 
Excellent for 
hydrophobic active 
ingredients 
Excellent for 
hydrophobic active 
ingredients 
Excellent for 
hydrophilic active 
ingredients 
Low encapsulation 
for all active 
ingredients 
     
Kinetic 
models 
First-order model First-order model Higuchi model 
Korsmeyer-Peppas 
model 
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The pathways taken for the release of sparingly water soluble active ingredient in each 
delivery carrier from donor chamber to receptor chamber of NLC, liposome, water-in-
oil microemulsion and κ-carrageenan-chitosan nanoparticle was illustrated as in the 
scheme as Figure 5.1(a), Figure 5.2(b), Figure 5.2(c) and Figure 5.2(d) respectively.  
 
  
(a) NLC 
 
(b) Liposome 
  
(c) Water-in-oil microemulsion 
 
(d) κ-carrageenan-chitosan nanoparticle 
Figure 5.1:  The proposed mechanism of the release of sparingly water soluble active ingredients in 
different delivery system. k0 with red arrow indicates the release of unencapsulated active 
ingredients from donor chamber into receptor chamber. k1, k2, and k3 with black arrow 
indicate the release of encapsulated active ingredients released from the respective delivery 
carrier. The color blue indicate aqueous phase whereas yellow color indicate oil phase. The 
size of the particle is in correlation to the size obtained from DLS. 
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5.2 Future work 
As a continuum of this research work, there are more aspects that can be explored: 
 In vitro cell culture studies to evaluate the possible cytotoxicity of the formulations 
on cell lines; 
 Irritancy test to assess the safety of the formulation for topical application; 
 In vivo animal studies to evaluate the efficacy and dosage for optimum therapeutic 
effect. 
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